Research activity information

• Short- and Long-Term Outcomes after Pancreatectomy for Pancreatic Cancer in Patients with Prior Esophagectomy for Esophageal Cancer.

  Jun Ishida, Yoshihide Nanno, Hirochika Toyama, Takuya Mizumoto, Dongha Lee, Takeshi Urade, Kenji Fukushima, Shohei Komatsu, Sadaki Asari, Hiroaki Yanagimoto, Masahiro Kido, Takumi Fukumoto

  BACKGROUND: Resection of pancreatic ductal adenocarcinoma (PDAC) after prior esophagectomy for esophageal cancer is technically demanding and its oncologic value is unclear. We evaluated the peri-operative safety and long-term survival after pancreatectomy for PDAC in this setting. METHODS: All patients undergoing pancreatectomy for PDAC at Kobe University Hospital (2017-2024) were reviewed. Outcomes in patients with previous esophagectomy for esophageal cancer were compared with those in patients undergoing contemporaneous resectable PDAC without such history. Primary endpoints were postoperative morbidity/mortality and overall survival. RESULTS: Of 415 pancreatectomies, nine (2.2%) had a history of esophagectomy for esophageal cancer (pancreaticoduodenectomy five; distal pancreatectomy four). Preservation of the gastrointestinal-conduit vessels was achieved in seven patients; two required right gastroepiploic artery and vein reconstruction. Major morbidity occurred in one patient (11.1%); there was no 90-day mortality and no conduit-related complication. However, only three patients (33.3%) received adjuvant chemotherapy. Median overall survival was significantly shorter in post-esophagectomy patients (n = 9) than in controls (n = 249) (8.4 vs. 41.7 months, p = 0.001). Survival after pancreaticoduodenectomy was especially poor (7.4 vs. 47.2 months, p < 0.001), whereas outcomes after distal pancreatectomy did not differ (16.4 vs. 38.9 months, p = 0.781). CONCLUSIONS: Pancreatectomy after esophagectomy can be performed safely, even with minimally invasive techniques, yet long-term survival remains dismal, particularly after pancreaticoduodenectomy. Careful patient selection with specific attention to the feasibility of delivering perioperative chemotherapy may be required to improve outcomes in this highly selected cohort.

  Feb. 2026, Annals of surgical oncology, 33(2) (2), 918 - 924, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Impact of intrahepatic lesions on lesion-specific response rates in patients with hepatocellular carcinoma treated with lenvatinib or immune checkpoint inhibitors.

  Masaki Omori, Shohei Komatsu, Toshifumi Tada, Nobuaki Ishihara, Takanori Matsuura, Eisuke Ueshima, Yoshimi Fujishima, Jun Ishihda, Masahiro Kido, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Hiroaki Yanagimoto, Keitaro Sofue, Yuzo Kodama, Takumi Fukumoto

  BACKGROUND: This study evaluated how lesion location affects treatment response and prognosis in hepatocellular carcinoma (HCC) patients treated with lenvatinib (LEN) or immune checkpoint inhibitors (ICIs; atezolizumab/bevacizumab or durvalumab/tremelimumab). Considering tumor microenvironment and heterogeneity, we analyzed lesion-specific responses to optimize therapy. METHODS: In this retrospective study, lesion-specific responses were assessed for intrahepatic lesions (IHLs), lung, lymph node, intra-abdominal, and other lesions; bone metastases were excluded due to evaluation limitations. Responses were measured using a modified size-based RECIST 1.1 method. Lesion-specific objective response rate (ORR) and disease control rate (DCR) were compared between LEN and ICI groups. RESULTS: ORR for IHLs was higher with ICIs than LEN (16.3 % vs. 3.5 %, P = 0.002). No significant differences were observed for lung, lymph node, or intra-abdominal lesions; adrenal metastases showed no response in either group. Subgroup analysis indicated better ORR and DCR for lung lesions treated with ICIs and lymph node lesions treated with LEN in patients without IHLs versus those with IHLs. CONCLUSIONS: ICIs achieved higher ORR in IHLs than LEN, with no significant differences for metastatic lesions. The presence of IHLs may influence distant lesion response, and therapeutic efficacy varies with treatment regimen.

  Nov. 2025, HPB : the official journal of the International Hepato Pancreato Biliary Association, English, International magazine

  Scientific journal


• Utility of Oncological Resectability Criteria in Recurrent Hepatocellular Carcinoma After Hepatectomy.

  Nobuaki Ishihara, Shohei Komatsu, Toshifumi Tada, Takanori Matsuura, Eisuke Ueshima, Keitaro Sofue, Masaki Omori, Masahiro Kido, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Kentaro Tai, Toshihiko Yoshida, Keisuke Arai, Hiroaki Yanagimoto, Yuzo Kodama, Takamichi Murakami, Takumi Fukumoto

  INTRODUCTION: Recurrent hepatocellular carcinoma (HCC) after hepatectomy remains a major clinical challenge, necessitating effective prognostic stratification. The oncological resectability criteria recently proposed by the Japan Liver Cancer Association and the Japanese Society of Hepato-Biliary-Pancreatic Surgery have not yet been validated in recurrent settings. This study aimed to evaluate the prognostic utility of these criteria in patients with recurrent HCC after hepatectomy. METHODS: This retrospective study included 505 patients with recurrent HCC following initial hepatectomy. Patients were classified into three groups-resectable (R), borderline resectable 1 (BR1), and borderline resectable 2 (BR2)-based on the oncological resectability criteria. Post-recurrence survival was evaluated using the Kaplan-Meier method, and multivariate analysis was performed to identify clinical factors associated with post-recurrence survival. RESULTS: Among the 505 patients, 248 patients were classified as R, 80 as BR1, and 177 as BR2. The median post-recurrence survival was 73.4 months for the R group, 33.6 months for the BR1 group, and 12.4 months for the BR2 group (p < 0.001). Multivariate analysis identified BR1/BR2 classification (p < 0.001), modified albumin-bilirubin grade 2b or 3 (p < 0.001), and recurrence within 1 year (p = 0.004) as independent predictors of poor post-recurrence survival. CONCLUSIONS: The oncological resectability criteria effectively stratified post-recurrence survival in patients with recurrent HCC. These findings suggest that a multidisciplinary approach may benefit patients with BR1 or BR2 recurrence. Further studies are warranted to explore optimal treatment strategies for recurrent HCC.

  Nov. 2025, Hepatology research : the official journal of the Japan Society of Hepatology, English, International magazine

  Scientific journal


• Prognostic Significance of GLIM-Defined Malnutrition in Patients With Resectable Pancreatic Adenocarcinoma Following Upfront Surgery.

  Takuya Mizumoto, Yoshihide Nanno, Jun Ishida, Dongha Lee, Kenji Fukushima, Shohei Komatsu, Hiroaki Yanagimoto, Sadaki Asari, Masahiro Kido, Takumi Fukumoto

  AIM: Regarding the resectability of pancreatic adenocarcinoma (PDAC), not only anatomical factors but also biological and conditional factors have come to be considered. This study examined the impact of the Global Leadership Initiative on Malnutrition (GLIM) criteria on prognosis after resection of anatomically resectable PDAC. METHODS: The medical records of consecutive patients who underwent resection for resectable PDAC between January 1, 2014, and December 31, 2022, were retrospectively reviewed. Patients were classified as normal, moderately, or severely malnourished according to the GLIM criteria. RESULTS: In total, 194 patients were included in the analysis. According to the GLIM criteria, 61 (31.4%), 49 (25.2%), and 84 (42.3%) patients were normal, moderately, and severely malnourished, respectively. Patients with malnutrition had shorter overall, recurrence-free, and disease-specific survival (OS, RFS, and DSS) than normal patients (OS, normal vs. moderate, p = 0.015; normal vs. severe, p < 0.001; RFS, normal vs. moderate p = 0.012, normal vs. severe, p < 0.001; DSS, normal vs. moderate, p = 0.023; normal vs. severe, p < 0.001). In multivariate analysis regarding OS using all factors, moderate or severe malnutrition according to the GLIM criteria (p = 0.007), performance status (p = 0.086), preoperative diabetes (p = 0.017), tumor diameter ≥ 3 cm (p = 0.002), lymph node metastasis (p < 0.001), and postoperative adjuvant therapy (p = 0.027) were independent prognostic factors. In multivariate analysis using preoperative factors, malnutrition according to the GLIM criteria remained a significant prognostic factor (p = 0.003). CONCLUSION: The GLIM criteria are effective prognostic predictors in patients with resectable PDAC undergoing upfront surgery. Preoperative nutritional assessment using these criteria may contribute to determining treatment plans for resectable PDAC.

  Nov. 2025, Annals of gastroenterological surgery, 9(6) (6), 1351 - 1361, English, Domestic magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Assessment of surgical difficulty in multiple laparoscopic liver resection using the aggregate value of scores based on the IWATE criteria.

  Daisuke Takimoto, Hidetoshi Gon, Shohei Komatsu, Kenji Fukushima, Takeshi Urade, Toshihiko Yoshida, Kentaro Tai, Keisuke Arai, Hiroaki Yanagimoto, Masahiro Kido, Takumi Fukumoto

  BACKGROUND: No studies exist regarding the methods for evaluating the surgical difficulty of multiple laparoscopic liver resection (MLLR). Hence, this study aimed to evaluate the usefulness of total scores calculated using the IWATE criteria for each resection site to assess the surgical difficulty of MLLR. METHODS: Medical records of patients who underwent MLLR at Kobe University Hospital between 2010 and 2023 were retrospectively reviewed. First, the total difficulty score was calculated for each patient by summing the IWATE criteria scores for all resection sites. Subsequently, we analyzed the correlation between this total difficulty score and surgical outcomes of MLLR. Finally, receiver operating characteristic analysis was employed to determine the optimal cutoff value of the total difficulty score. This cutoff value was used to categorize patients into the high- and low-total difficulty score groups, allowing for a comparison of their surgical outcomes. RESULTS: This study included 63 patients. The total difficulty score correlated with operation time [r = 0.54, 95% confidential interval (CI): 0.34-0.70, P < 0.001] and blood loss (r = 0.27, 95% CI: 0.03-0.90, P = 0.029), and was associated with postoperative complications (odds ratio: 1.33, 95% CI: 1.14-1.60, P < 0.001). Patients with total difficulty scores ≤ 11 and ≥ 12 were included in the low- and high-score groups, respectively. The high-score group exhibited longer operation times (481 min vs. 372 min, P = 0.001), greater blood loss (110 ml vs. 50 ml, P = 0.005), and higher overall complication rates (71% vs. 29%, P = 0.001) than the low-score group. CONCLUSIONS: The total difficulty score based on the IWATE criteria may be a useful tool for assessing surgical difficulty in MLLR.

  Oct. 2025, Surgical endoscopy, English, International magazine

  Scientific journal


• Multidisciplinary strategies including local treatment to achieve drug-free status after atezolizumab plus bevacizumab treatment in hepatocellular carcinoma.

  Nobuaki Ishihara, Shohei Komatsu, Yoshihiko Yano, Yoshimi Fujishima, Jun Ishida, Masahiro Kido, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Hiroaki Yanagimoto, Hirochika Toyama, Yuzo Kodama, Takumi Fukumoto

  Atezolizumab plus bevacizumab (AteBev) is used as a first-line treatment for advanced hepatocellular carcinoma (HCC). Combining AteBev with sequential local treatment holds potential; however, optimal timing, modality and continuation of systemic chemotherapy remain undetermined. In the present study, a retrospective analysis of 123 patients with HCC treated with AteBev at two institutions was performed. Patients with no apparent residual lesions after sequential local treatment or AteBev treatment alone were followed up without any systemic chemotherapy ('drug-free' cohort). Outcomes focused on the impact of achieving 'drug-free' status, with timing assessed based on tumor size and α-fetoprotein levels. The results revealed that serum α-fetoprotein levels and tumor shrinkage plateaued at ~3 and 6 months post-AteBev treatment, respectively. Patients achieving 'drug-free' status demonstrated prolonged median survival (P<0.001) and progression-free survival (P<0.001), comparable with patients with 'clinical complete response' or 'drug-off' statuses. Moreover, particle radiotherapy was the most common local treatment modality. In conclusion, achieving a 'drug-free' status was associated with favorable prognoses. Optimal timing for sequential local treatment is suggested as 3-6 months after AteBev initiation, with multidisciplinary strategies to achieve 'drug-free' status offering a promising option for the treatment of advanced HCC.

  Oct. 2025, Oncology letters, 30(4) (4), 466 - 466, English, International magazine

  Scientific journal


• Exploring the potential utility of modified difficulty scores based on the IWATE criteria for assessing the surgical difficulty of laparoscopic repeat liver resection.

  Hidetoshi Gon, Shohei Komatsu, Tatsuki Kusuhara, Daisuke Takimoto, Kenji Fukushima, Takeshi Urade, Toshihiko Yoshida, Kentaro Tai, Keisuke Arai, Hiroaki Yanagimoto, Masahiro Kido, Takumi Fukumoto

  BACKGROUND: Laparoscopic repeat liver resection (LRLR) is more challenging than initial laparoscopic liver resection in some cases because of intra-abdominal adhesions and liver deformation caused by previous operations. However, there are insufficient reports on difficulty scoring systems for LRLR. In this study, we aimed to explore whether the IWATE criteria and its modified scoring system could effectively predict surgical outcomes in patients undergoing LRLR. METHODS: Patients who underwent LRLR at the Kobe University Hospital between 2014 and 2024 were enrolled. We assessed the correlation between difficulty scores based on the IWATE criteria and LRLR surgical outcomes. The correlation between the modified difficulty scores and LRLR surgical outcomes were also evaluated. The modified difficulty scores were calculated by adding 2 points for ipsilateral recurrence and 1 point for a previous history of open liver resection to the original difficulty scores of the IWATE criteria. RESULTS: Eighty-four patients who underwent LRLR were enrolled. The median value of the IWATE criteria and modified difficulty score was 4 and 6, respectively. The median operation time and blood loss were 287 min and 10 mL, respectively. Nineteen (23%) patients experienced postoperative complications, wherein four (5%) had Clavien-Dindo grade ≥ IIIa complications. The IWATE criteria difficulty score correlated with operation time (r = 0.52, 95% confidential interval CI 0.35-0.66, P < 0.001) and blood loss (r = 0.26, 95% CI 0.05-0.45, P = 0.018), while the modified difficulty score correlated with operation time (r = 0.53, 95% CI 0.36-0.67, P < 0.001), blood loss (r = 0.31, 95% CI 0.11-0.49, P = 0.004), and overall postoperative complications (odds ratio 1.34 [interquartile range 1.23, 1.47], P = 0.019). CONCLUSIONS: The IWATE criteria and modified difficulty score may be useful for assessing LRLR surgical difficulty. Additionally, the modified difficulty score may more precisely predict the risk of postoperative complications.

  Sep. 2025, Surgical endoscopy, 39(12) (12), 8228 - 8236, English, International magazine

  Scientific journal


• Association Between Postoperative Complications Assessed by the Comprehensive Complication Index (CCI) and Early Recurrence after Pancreaticoduodenectomy for Biliary Tract Cancer.

  Yuki Okazoe, Hiroaki Yanagimoto, Daisuke Tsugawa, Masayuki Akita, Michihiko Yoshida, Ryunosuke Konaka, Toru Takahashi, Yoshihide Nanno, Takeshi Urade, Kenji Fukushima, Shohei Komatsu, Sadaki Asari, Masahiro Kido, Takumi Fukumoto

  BackgroundThis study aimed to evaluate the impact of postoperative complications on early recurrence (ER) after pancreaticoduodenectomy (PD) for biliary tract cancer (BTC).MethodsPatients who underwent PD for BTC between 2009 and 2022 were enrolled in this study. Postoperative complications were assessed using the comprehensive complication index (CCI), calculated by summing all the complications. The optimal CCI cutoff value for predicting ER was selected based on the minimum P value from the chi-square test. ER was defined as recurrence within 12 months of resection. Risk factors for ER were identified using multivariate analysis.ResultsA total of 118 patients were analyzed. ER was observed in 34 (28.8 %) patients, indicating a significantly poorer prognosis than those without ER (log-rank, P < .001). No significant differences were observed in the primary tumor site or pathological features between the low CCI (<42.6) and high CCI (≥42.6) groups. The incidence of ER was significantly higher in the high CCI group than in the low CCI group (50.0% vs 24.0%, P = .015). Multivariate analysis revealed that high CCI (odds ratio [OR] 4.43, 95% confidence interval [CI] 1.41-13.97, P = .011) and R1 resection (OR 4.88, 95% CI 1.43-16.70, P = .012) were independent risk factors for ER.DiscussionPostoperative complications after PD for BTC were found to be independent risk factors for ER.

  Aug. 2025, The American surgeon, 31348251368282 - 31348251368282, English, International magazine

  Scientific journal


• Using the comprehensive complication index to assess the impact of Global Leadership Initiative on Malnutrition (GLIM)-defined malnutrition on postoperative complications after resection for biliary tract cancer.

  Yuki Okazoe, Hiroaki Yanagimoto, Daisuke Tsugawa, Masayuki Akita, Takuya Mizumoto, Toshihiko Yoshida, Shinichi So, Jun Ishida, Takeshi Urade, Yoshihide Nanno, Kenji Fukushima, Hidetoshi Gon, Shohei Komatsu, Sadaki Asari, Hirochika Toyama, Masahiro Kido, Takumi Fukumoto

  PURPOSE: The Global Leadership Initiative on Malnutrition (GLIM) criteria, proposed in 2018, provide universal diagnostic standards for malnutrition, a known risk factor for postoperative complications in patients with various cancers. However, its impact on surgery for biliary tract cancer (BTC) remains unclear. This study evaluates the relationship between GLIM-defined malnutrition and postoperative complications after resection for BTC. METHODS: The subjects of this retrospective study were patients who underwent pancreaticoduodenectomy or major hepatectomy with extrahepatic bile duct resection for BTC between January, 2013 and December, 2021. The comprehensive complication index (CCI), an indicator of postoperative complications, was calculated based on the total number and severity of postoperative complications. RESULTS: GLIM-defined malnutrition was diagnosed in143 (71.1%) of the total 201 patients. The median CCI was significantly higher in the GLIM-defined malnutrition group than in the non-malnutrition group (37.2 vs. 28.3; P < 0.001). Multivariate logistic regression analysis revealed that GLIM-defined malnutrition (odds ratio 2.87 [95% confidence interval 1.38-5.96], P = 0.005) and intraoperative blood loss > 1,000 mL (odds ratio 3.77 [95% confidence interval 1.06-13.47], P = 0.041) were independent predictors of high morbidity (CCI ≥ 37.1). CONCLUSION: Preoperative GLIM-defined malnutrition was closely associated with increased postoperative complications in patients who underwent resection for BTC.

  May 2025, Surgery today, 55(11) (11), 1598 - 1608, English, Domestic magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Impact of a dilated main pancreatic duct in the expected remnant pancreas on the incidence of clinically significant remnant pancreatic lesion after resection of noninvasive and microinvasive intraductal papillary mucinous neoplasms.

  Takuya Mizumoto, Hirochika Toyama, Yoshihide Nanno, Jun Ishida, Yuichiro Uchida, Hideaki Iwama, Masayuki Kojima, Takeshi Takahara, Koichi Suda, Kenji Fukushima, Hidetoshi Gon, Shohei Komatsu, Hiroaki Yanagimoto, Masahiro Kido, Takumi Fukumoto

  BACKGROUND: Partial pancreatectomies for intraductal papillary mucinous neoplasms (IPMN) often leave a dilated main pancreatic duct (MPD). However, its impact on the development of remnant pancreatic lesions is unknown. METHODS: Medical records of consecutive patients who underwent partial pancreatectomy for noninvasive or microinvasive IPMN with dilated MPD on preoperative imaging between April 2007 and March 2023 at two tertiary referral centers in Japan were retrospectively reviewed. A dilated remnant MPD (DRM) was defined as an MPD diameter of the expected remnant pancreas of ≥5 mm. The clinically significant remnant pancreatic lesion (CSRPL) was defined as a remnant pancreatic lesion which requires intervention. RESULTS: A total of 172 patients (106 males and 66 females) were analyzed. Preoperatively, 132 patients (76.7 %) had mixed-type IPMN and 40 (23.1 %) had main duct IPMN. Among them, 16 patients (9.3 %) had CSRPL at 1569 days (median; range, 120-5503 days) after the initial surgery. In the preoperative imaging analysis, 104 patients (60.5 %) had DRM. The univariate analysis revealed that high-grade or micro-invasive pathology (p = 0.013) was significantly associated with CSRPL, whereas DRM was inversely associated with CSRPL (p = 0.021). The multivariate analysis revealed that the trends of DRM (p = 0.002) and high-grade/micro-invasive pathology (p = 0.003) remained significant. CONCLUSIONS: Leaving a dilated MPD did not increase but instead inversely associated with the incidence of CSRPL after IPMN resection. It was suggested that preserving the pancreas, including the dilated MPD, is oncologically safe if the lesion of interest can be resected.

  May 2025, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 25(3) (3), 440 - 449, English, International magazine

  Scientific journal


• Biomarker-guided strategy for Denver peritoneovenous shunts in refractory ascites: a retrospective single-center study.

  Yuhi Shimura, Shohei Komatsu, Yoshimasa Hashimoto, Miho Nishio, Yu Hashimoto, Michihiko Yoshida, Toshihiko Yoshida, Kenji Fukushima, Itsuo Fujita, Takumi Fukumoto

  PURPOSE: This study aimed to evaluate the utility of peritoneovenous shunt (PVS) placement for refractory ascites (RA) based on preoperative biomarkers. METHODS: This retrospective cohort study included patients with malignant and cirrhotic RA undergoing PVS placement treated at Sumoto Itsuki Hospital between January 2001 and March 2024. The efficacy of PVSs was defined according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE). The usefulness of the prognostic nutritional index, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, and C-reactive protein-to-albumin ratio as prognostic indicators for the efficiency of PVS was evaluated. RESULTS: In total, 149 consecutive patients (malignant RA, n = 100; cirrhotic RA, n = 49) were included in this study. PVS placement satisfied the efficacy criteria for ascites in 102 (68%) patients in the entire cohort. The estimated glomerular filtration rate (eGFR) ≤ 30 mL/min/1.73 m2 was an independent predictor for the inefficacy of PVSs (odds ratio: 2.82, 95% CI: 1.04-7.73, P = 0.042). Based on receiver operating characteristic curve and multivariate analysis of the entire cohort, NLR ≥ 5.8 was an independent risk factor for death within 1 week after PVS placement (odds ratio: 18.2, 95% CI: 2.07-29.7, P = 0.016). CONCLUSION: PVS placement for RA may be a treatment option when preoperative eGFR is > 30 mL/min/1.73 m2 and NLR is < 5.8.

  Apr. 2025, Langenbeck's archives of surgery, 410(1) (1), 140 - 140, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Achieving textbook outcome in liver resection for hepatocellular carcinoma: malnutrition's pivotal role.

  Kentaro Oji, Takeshi Urade, Satoshi Omiya, Masahiro Kido, Shohei Komatsu, Hidetoshi Gon, Kenji Fukushima, Hiroaki Yanagimoto, Hirochika Toyama, Takumi Fukumoto

  PURPOSE: To investigate the impact of textbook outcome (TO) achievement on survival post-liver resection for hepatocellular carcinoma (HCC) and explore the associated factors. METHODS: We retrospectively reviewed 330 patients diagnosed with HCC who underwent initial liver resection at our hospital between January 2011 and December 2019. We also investigated the achievement rates of five TOs and sub-analyzed the relationship between them and malnutrition. The patient's nutritional status was classified following the Global Leadership Initiative on Malnutrition (GLIM) criteria. RESULTS: The TO achievement rate was 72.7%. In the prognostic analysis, the TO-achieving group showed significantly longer overall survival (OS) and recurrence-free survival (RFS). Significant differences in age, body mass index, weight loss, muscle mass, serum aspartate aminotransferase level, serum protein induced by vitamin K absence or antagonist-II, tumor characteristics, intraoperative blood loss, perioperative transfusion, and nutritional status were found between the groups. CONCLUSIONS: TO achievement is associated with OS and RFS post-liver resection for HCC. The TO is valuable for evaluating treatment quality in liver resection. Additionally, malnutrition graded following the GLIM criteria, age, tumor stage, and intraoperative blood loss are independent factors for achieving a TO post-liver resection for HCC.

  Apr. 2025, Langenbeck's archives of surgery, 410(1) (1), 139 - 139, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Comparison of the surgical difficulty between segment 7 and 8 partial liver resection untilizing the laparoscopic and open approaches.

  Hidetoshi Gon, Akihiro Fujisawa, Shohei Komatsu, Motofumi Tanaka, Kenji Fukushima, Takeshi Urade, Toshihiko Yoshida, Keisuke Arai, Jun Ishida, Yoshihide Nanno, Daisuke Tsugawa, Hiroaki Yanagimoto, Hirochika Toyama, Masahiro Kido, Takumi Fukumoto

  PURPOSE: We aimed to investigate the differences in surgical difficulty between laparoscopic partial liver resections of segments 7 and 8. METHODS: We analyzed 173 patients who underwent partial liver resections of segments 7 or 8 between 2010 and 2022 at two institutions. We investigated differences in the surgical outcomes of each procedure using propensity score matching. We compared these outcomes with those of open partial liver resections for segments 7 and 8 to determine whether the differences were unique to the laparoscopic approach. RESULTS: Thirty and 54 patients underwent laparoscopic partial liver resections of segments 7 and 8. In the matched cohort (22 in each group), the operation time was significantly longer (377 vs. 278 min, P = 0.020) and the proportion of postoperative complications significantly higher in segment 7 (27% vs. 0%, P = 0.008). Forty-one and 48 patients underwent open partial liver resections of segments 7 and 8, respectively. There were no significant differences in the surgical outcomes between the segments in the matched cohort (20 in each group). CONCLUSIONS: Laparoscopic partial liver resections of segment 7 may be more challenging than that of segment 8. This difference in difficulty was not observed in open partial liver resections.

  Apr. 2025, Surgery today, 55(10) (10), 1383 - 1392, English, Domestic magazine

  Scientific journal


• Treatment outcomes of hepatectomy and systemic chemotherapy based on oncological resectability criteria for hepatocellular carcinoma.

  Shohei Komatsu, Yoshihiko Yano, Nobuaki Ishihara, Masahiro Kido, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Hiroaki Yanagimoto, Hirochika Toyama, Takumi Fukumoto

  AIM: The oncological resectability criteria for hepatocellular carcinoma (HCC) have recently been established (R/BR1/BR2), and validating the outcomes is an urgent issue. This study aimed to analyze the outcomes of hepatectomy and systemic chemotherapy based on the oncological resectability criteria. METHODS: A total of 931 patients in the hepatectomy group and 273 in the systemic chemotherapy group who received atezolizumab/bevacizumab, lenvatinib, or durvalumab plus tremelimumab were recruited. RESULTS: The median survival times (MST) in the hepatectomy group were R, 107.2 mo; BR1, 44.4 mo; and BR2, 18.4 mo (p < 0.0001). The MSTs in the systemic chemotherapy group were R, 16.3 mo; BR1, 24.5 mo; and BR2, 16.1 mo (p = 0.3598). A comparison of survival of patients in the BR2 category revealed no significant difference between the two groups for those with modified albumin-bilirubin grade 1 + 2a (p = 0.7343) and grade 2b + 3 (p = 0.6589). The BR2 definition comprised three tumor factors, and the MST of patients with only one BR2-defining factor tended to be better in the hepatectomy group than in the systemic chemotherapy group (22.9 vs 20.2 mo, p = 0.0977). Meanwhile, the MST tended to be better in the systemic chemotherapy group than in the hepatectomy group (16.5 vs 12.6 mo) for those with two to three BR2-defining factors, although the difference was insignificant (p = 0.4252). CONCLUSION: The oncological resectability criteria for HCC effectively stratified the prognosis after hepatectomy. Treatment outcomes of hepatectomy in patients with two to three BR2-defining factors are limited, suggesting the need for multidisciplinary treatment.

  Mar. 2025, Annals of gastroenterological surgery, 9(2) (2), 235 - 243, English, Domestic magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Impact of depth of body cavity at the upper-right portion of the abdomen on open and laparoscopic liver resection of segment 7.

  Hidetoshi Gon, Shohei Komatsu, Hirotoshi Soyama, Motofumi Tanaka, Masahiro Kido, Kenji Fukushima, Takeshi Urade, Shinichi So, Toshihiko Yoshida, Keisuke Arai, Daisuke Tsugawa, Hiroaki Yanagimoto, Hirochika Toyama, Takumi Fukumoto

  PURPOSE: The impact of body-cavity depth on open (OLR) and laparoscopic liver resection (LLR) of segment 7 remains unclear. Therefore, we investigated the influence of body-cavity depth at the upper-right portion of the abdomen on LLR and OLR of segment 7. METHODS: In total, 101 patients who underwent segment-7 liver resection over 2010-2023 were included. Body-cavity depth was measured from the abdominal-wall surface to the deepest site on the right side of the liver. Patients were categorized into shallow (< 18.4 cm) and deep (≥ 18.4 cm) populations based on median body-cavity depth. We compared surgical outcomes between OLR and LLR in shallow and deep populations after propensity-score adjustments. RESULTS: In OLR and LLR groups, 27 and 22 patients in the shallow population, respectively, and 26 and 26 patients were included in the deep population, respectively, were included. The OLR group in the deep population had significantly greater blood loss than the corresponding LLR group (difference: 144 mL, 95% confidence interval (CI): [50, 238], P = 0.004). Other surgical outcomes, including operative time, were similar between groups. In the shallow population, the OLR group had significantly shorter operative time (difference: - 54 mL, 95% CI: [-101, - 6], P = 0.028) and similar blood loss than the LLR group. CONCLUSIONS: For segment-7 liver resection, LLR is likely favorable for patients with a deep body cavity, with similar operative time and lower blood loss compared to OLR. Body-cavity depth could be a useful indicator for determining the suitable surgical approach for segment-7 liver resection.

  Jan. 2025, Langenbeck's archives of surgery, 410(1) (1), 37 - 37, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Efficacy and safety of indocyanine green-fluorescence imaging guided liver resection: a single-arm prospective cohort study.

  Hidetoshi Gon, Satoshi Omiya, Shohei Komatsu, Nobuaki Yamasaki, Sae Murakami, Kenji Fukushima, Takeshi Urade, Daisuke Tsugawa, Hiroaki Yanagimoto, Hirochika Toyama, Masahiro Kido, Takumi Fukumoto

  PURPOSE: This study aimed to evaluate the efficacy of indocyanine green (ICG)-fluorescence imaging for the identification of hepatic boundaries during liver resection and its advantages in surgical outcomes over conventional methods. METHODS: This prospective, exploratory, single-arm clinical trial included 47 patients with liver tumors who underwent liver resection using ICG-fluorescence imaging (ICG-LR) between 2019 and 2020. The primary outcome measure was the successful identification of hepatic boundaries during liver resection, from the perspective of both the hepatic surface and intrahepatic boundary, using ICG-fluorescence imaging. The secondary outcomes comprised surgical outcomes. Using propensity score matching (PSM), the surgical outcomes were subsequently compared between the ICG-LR group and patients who underwent conventional liver resection (C-LR, n = 100) between 2017 and 2018. RESULTS: Hepatic boundaries were successfully identified in 28 patients (60%; 95% confidence interval, 45-72%), including 21 and 7 who underwent anatomical and non-anatomical liver resection, respectively. After PSM, 40 patients were included in each of the ICG-LR and C-LR groups. The surgical outcomes were similar between the groups. Subsequently, surgical outcomes were compared between the groups focusing on anatomical liver resection. After PSM, 21 patients were included in each group. The ICG-LR group had a lower rate of Clavien-Dindo grade ≥ IIIa complications (0% vs. 24%; P = 0.017), including ascites and bile leak, and a shorter hospital stay (12 vs. 14 days, P = 0.041) than the C-LR group did. CONCLUSION: ICG-fluorescence imaging could be used to recognize hepatic boundaries during liver transection. Additionally, ICG-LR may be useful in preventing severe liver-associated complications. TRIAL REGISTRATION NUMBER: This study is registered at the UMIN Clinical Trials Registry: UMIN0000180139 and Japan Registry of Clinical Trials: jRCT1051180070. The Registration Data Set is available at https://jrct.niph.go.jp/ .

  Jan. 2025, Langenbeck's archives of surgery, 410(1) (1), 34 - 34, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• GLIM Criteria as Prognostic Factor in Patients Undergoing Adjuvant S-1 Chemotherapy for Biliary Tract Cancer.

  Ryunosuke Konaka, Hiroaki Yanagimoto, Daisuke Tsugawa, Masayuki Akita, Takuya Mizumoto, Toshihiko Yoshida, Shinichi Sou, Jun Ishida, Yoshihide Nanno, Takeshi Urade, Kenji Fukushima, Hidetoshi Gon, Shohei Komatsu, Sadaki Asari, Masahiro Kido, Hirochika Toyama, Takumi Fukumoto

  BACKGROUND/AIM: Biliary tract cancers (BTCs) have poor prognoses, with limited curative options beyond surgical resection. Adjuvant S-1 chemotherapy has shown survival benefits in Japanese patients undergoing resection for BTC. However, prognostic factors influencing survival in these patients remain uncertain. In this study, we aimed to investigate the efficacy of preoperative nutritional status using the Global Leadership Initiative on Malnutrition (GLIM) criteria as a prognostic factor in patients receiving adjuvant S-1 chemotherapy for BTC. PATIENTS AND METHODS: In this retrospective study, excluding intrahepatic cholangiocarcinoma, we evaluated 58 patients who underwent curative surgery for BTC at Kobe University from 2013 to 2022, followed by adjuvant S-1 chemotherapy. Nutritional status was classified by GLIM criteria into normal/moderate and severe malnutrition groups. Overall (OS) and recurrence-free (RFS) survival were analyzed using Kaplan-Meier and Cox proportional hazards models. RESULTS: Of the 58 patients, 3.4% had no malnutrition, 72.5% had moderate malnutrition, and 24.1% had severe malnutrition. Patients with severe malnutrition had significantly worse 5-year OS (24.7% vs. 52.5%, p=0.0014) and RFS (34.3% vs. 52.0%, p=0.0066). Severe malnutrition was an independent prognostic factor for poorer OS (hazard ratio=3.40, 95% confidence interval=1.46-7.94; p=0.0047) and RFS (hazard ratio=2.48, 95% confidence interval=1.07-5.76; p=0.035). No significant difference in S-1 completion rates was observed. CONCLUSION: Severe malnutrition, as defined by GLIM criteria, is a poor prognostic factor in patients with BTCs undergoing adjuvant S-1 chemotherapy.

  2025, Cancer diagnosis & prognosis, 5(5) (5), 557 - 565, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Usefulness of A Portal Vein Stent for Sinistral Portal Hypertension: A Case Report.

  Daisuke Takimoto, Jun Ishida, Hirochika Toyama, Yoshihide Nanno, Takuya Mizumoto, Toshihiko Yoshida, Takeshi Urade, Kenji Fukushima, Hidetoshi Gon, Daisuke Tsugawa, Shohei Komatsu, Hiroaki Yanagimoto, Masahiro Kido, Takumi Fukumoto

  INTRODUCTION: Portal vein (PV) and splenic vein (SV) stenosis are known complications of pancreatoduodenectomy (PD) and often lead to portal hypertension. PV stenosis extending to the SV confluence can result in sinistral portal hypertension (SPH), characterized by gastrointestinal varices and splenomegaly in the presence of normal liver function. There is no standardized treatment strategy for SPH following PD. CASE PRESENTATION: A 42-year-old female underwent robot-assisted PD for a pancreatic neuroendocrine tumor without immediate PV complications. Postoperatively, the patient experienced fluid retention; however, this did not pose a problem, and no therapeutic intervention was necessary. Two months later, imaging revealed PV stenosis and SV obstruction. Eleven months after surgery, the patient presented with melena, and imaging confirmed the presence of gastroesophageal varices with severe PV stenosis and complete SV obstruction. Endoscopic variceal ligation was performed, and the hemodynamic status of the portal system was assessed using computed tomography during arterial portography (CTAP). CTAP showed communication between the superior mesenteric vein and the SV via the middle colic vein. Therefore, we decided to perform PV stenting. The stent was successfully placed, resulting in a significant improvement in the esophageal varices. The patient was discharged on postoperative day 4, receiving anticoagulant therapy, with no further complications. CONCLUSIONS: This case demonstrates the efficacy of PV stenting after careful hemodynamic assessment in a patient who developed SPH due to PV stenosis and SV obstruction following PD.

  2025, Surgical case reports, 11(1) (1), English, Domestic magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Treatment Outcomes of Tyrosine Kinase Inhibitors and Durvalumab Plus Tremelimumab After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma.

  Nobuaki Ishihara, Shohei Komatsu, Yoshihiko Yano, Yoshimi Fujishima, Jun Ishida, Masahiro Kido, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Toshihiko Yoshida, Kentaro Tai, Keisuke Arai, Hiroaki Yanagimoto, Hirochika Toyama, Takanori Matsuura, Toshifumi Tada, Yuzo Kodama, Takumi Fukumoto

  BACKGROUND/AIM: Atezolizumab plus bevacizumab (AteBev) is widely used as a first-line treatment for advanced hepatocellular carcinoma (HCC). However, evidence regarding the optimal drug sequence following AteBev treatment is limited. This study aimed to compare the treatment outcomes between tyrosine kinase inhibitors (TKIs) and durvalumab plus tremelimumab (DurTre) following AteBev treatment. PATIENTS AND METHODS: Overall, 134 consecutive patients who received AteBev for advanced HCC were enrolled in this study. Treatment outcomes were retrospectively compared between TKIs (AteBev→TKI group) and DurTre (AteBev→DurTre group). RESULTS: The AteBev→TKI and Ate→DurTre groups included 46 and 7 patients, respectively. The AteBev→TKI group had significantly longer median progression-free survival after second-line treatment (3.6 vs. 0.94 months, p<0.001). The disease control rate was significantly higher in the AteBev→TKI group (p=0.020). The serum alpha-fetoprotein levels significantly decreased at one month in the AteBev→TKI group (0.909 vs. 1.435, p=0.035), whereas the albumin-bilirubin score significantly decreased at one month in the AteBev→TKI group (0.875 vs. 0.952, p=0.017). Each group reported no new unmanageable adverse events. CONCLUSION: TKIs may be a more optimal drug sequence than DurTre after AteBev treatment from an oncological perspective. TKIs following AteBev treatment require careful monitoring for deteriorating liver function.

  Jan. 2025, Anticancer research, 45(1) (1), 251 - 260, English, International magazine

  Scientific journal


• Laparoscopic Liver Resection for Hepatocellular Adenomas in Pediatric Glycogen Storage Disease Type Ia: A Case With Consideration for Future Transplantation.

  Kentaro Oji, Takeshi Urade, Ryosuke Bo, Masahiro Kido, Shohei Komatsu, Hidetoshi Gon, Kenji Fukushima, Shinichi So, Toshihiko Yoshida, Kentaro Tai, Keisuke Arai, Takumi Fukumoto

  A 13-year-old girl presented with enlarging hepatocellular adenomas and a history of glycogen storage disease type Ia. Her liver function was well controlled by nutritional therapy. The options of resection and transplantation were considered, and the patient was successfully treated with laparoscopic liver resection. However, pathology revealed fatty liver, indicating that subsequent surgical treatment may be necessary. Herein, we report the patient's clinical progress, including the strategy for determining the surgical approach. In cases where the patient is a low priority for transplantation, laparoscopic liver resection is an important therapeutic choice, even though regrowth of residual lesions has been reported.

  2025, Asian journal of endoscopic surgery, 18(1) (1), e70090, English, Domestic magazine

  Scientific journal


• [A Case of Neuroendocrine Carcinoma of the Bile Duct Treated by R0 Resection through Laparoscope-Assisted Pancreaticoduodenectomy].

  Michihiko Yoshida, Hiroaki Yanagimoto, Daisuke Tsugawa, Masayuki Akita, Yoshihide Nanno, Takeshi Urade, Kenji Fukushima, Hidetoshi Gon, Shouhei Komatsu, Sadaki Asari, Takayuki Kodama, Masahiro Kido, Hirochika Toyama, Tomoo Ito, Takumi Fukumoto

  The patient was a 76-year-old man who presented with dark urine, white stools, and jaundice. He was suspected of having distal bile duct cancer and was referred to our hospital. A second biopsy was performed at our hospital, and the patient was diagnosed with primary neuroendocrine carcinoma(NEC)of the bile duct. A laparoscope-assisted subtotal stomach-preserving pancreaticoduodenectomy was performed, and postoperative pathological diagnosis was primary bile duct NEC, pT3pN2cM0, pStage ⅢA. The patient had an uneventful postoperative course and was discharged 20 days after surgery. After discharge, the patient received 4 courses of CBDCA+VP-16 as postoperative adjuvant chemotherapy. He has remained recurrence-free for 13 months after surgery.

  Dec. 2024, Gan to kagaku ryoho. Cancer & chemotherapy, 51(13) (13), 1633 - 1635, Japanese, Domestic magazine

  Scientific journal


• Preoperative level of serum transthyretin as a novel biomarker predicting survival in resected pancreatic ductal adenocarcinoma with neoadjuvant therapy.

  Yoshihide Nanno, Hirochika Toyama, Takuya Mizumoto, Jun Ishida, Takeshi Urade, Kenji Fukushima, Hidetoshi Gon, Daisuke Tsugawa, Shohei Komatsu, Sadaki Asari, Hiroaki Yanagimoto, Masahiro Kido, Takumi Fukumoto

  BACKGROUND: Systemic inflammation and altered metabolism are essential hallmarks of cancer. We hypothesized that the rapid turnover protein transthyretin (TTR) (half-life: 2-3 days), compared with the conventional marker albumin (21 days), better reflects the inflammatory/metabolic dynamics of pancreatic ductal adenocarcinoma (PDAC) after neoadjuvant therapy (NAT) and is a useful prognostic marker. METHODS: Serum TTR and albumin levels were measured in 104 consecutive post-NAT PDAC patients before curative resection. The associations of preoperative TTR and albumin levels with overall survival (OS) after pancreatectomy were retrospectively analyzed. RESULTS: The mean (SD) TTR and albumin levels were 21.6 (6.4) mg/dL (normal range: ≥22.0 mg/dL) and 3.9 (0.55) g/dL. A low (<22.0 mg/dL) post-NAT TTR level was associated with an advanced tumor stage and higher CEA and CRP levels. Patients with low TTR levels showed significantly worse OS compared with normal levels (3-year OS 39 % vs. 54 %, P = 0.037), although albumin levels did not. We modified prognostic biomarkers of systemic inflammation/metabolism, such as GPS, PNI, and CONUT scores, using the serum TTR instead of albumin level and successfully showed that modified scores were better associated with OS compared with original scores using serum albumin level. CONCLUSIONS: Our data suggest that the TTR level is a promising prognostic biomarker for PDAC patients after NAT.

  Sep. 2024, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 24(6) (6), 917 - 924, English, International magazine

  Scientific journal


• Comparison of laparoscopic liver resection for the ventral versus the dorsal areas of segment 8.

  Kentaro Oji, Takeshi Urade, Masahiro Kido, Shohei Komatsu, Hidetoshi Gon, Nobuaki Yamasaki, Kenji Fukushima, Shinichi So, Toshihiko Yoshida, Keisuke Arai, Masayuki Akita, Jun Ishida, Yoshihide Nanno, Daisuke Tsugawa, Sadaki Asari, Hiroaki Yanagimoto, Hirochika Toyama, Takumi Fukumoto

  PURPOSE: The technical difficulties of laparoscopic liver resection (LLR) are greatly associated with the location of liver tumors. Since segment 8 (S8) contains a wide area, the difficulty of LLR for S8 tumors may vary depending on the location within the segment, such as the ventral (S8v) and dorsal (S8d) area, but the difference is unclear. METHODS: We retrospectively investigated 30 patients who underwent primary laparoscopic partial liver resection for liver tumors in S8 at Kobe University Hospital between January 2018 and June 2023. RESULTS: Thirteen and 17 patients underwent LLR for S8v and S8d, respectively. The operation time was significantly longer (S8v 203[135-259] vs. S8d 261[186-415] min, P = 0.002) and the amount of blood loss was significantly higher (10[10-150] vs. 10[10-200] mL, P = 0.034) in the S8d group than in the S8v group. No significant differences were observed in postoperative complications or postoperative length of hospital stay. Additionally, intraoperative findings revealed that the rate at which the case performed partial liver mobilization in the S8d group was higher (2[15.4%] vs. 8[47.1%], P = 0.060) and the median parenchymal transection time of the S8d group was longer (102[27-148] vs. 129[37-175] min, P = 0.097) than those in the S8v group, but there were no significant differences. CONCLUSION: The safety of LLR for the S8d was comparable to that of LLR for S8v, although LLR for S8d resulted in longer operative time and more blood loss. THE TRIAL REGISTRATION NUMBER: B230165 (approved at December 26, 2023).

  Aug. 2024, Langenbeck's archives of surgery, 409(1) (1), 243 - 243, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• [A Case of Radical Hepatectomy in a Patient with Recurrent Liver Metastasis of Gallbladder Cancer after Successful Chemotherapy with GC+Durvalumab].

  Taiichiro Miyake, Takeshi Urade, Shohei Komatsu, Hidetoshi Gon, Kenji Fukushima, Shinichi So, Keisuke Arai, Sadaki Asari, Hiroaki Yanagimoto, Hirochika Toyama, Masahiro Kido, Takumi Fukumoto

  A 49-year-old man underwent an open cholecystectomy for advanced gallbladder cancer in 2021. Three months after surgery, the patient underwent an additional resection, which showed no malignant findings, but 12 months after surgery, contrast-enhanced CT and MRI showed a new mass lesion in segment 8 of the liver, and the patient was diagnosed with postoperative hepatic metastatic recurrence of gallbladder cancer. After referral to our institution, he received 1 course of gemcitabine+cisplatin(GC)therapy and 8 courses of gemcitabine+cisplatin+durvalumab(GCD)therapy. Contrast- enhanced CT and MRI showed that the metastases had shrunk, and PET scan showed no FDG accumulation. Two months after completion of chemotherapy, there was no evidence of metastatic enlargement and new metastasis including distant metastasis, and the patient was referred to our department. Since curative resection was expected, a laparoscopic partial hepatectomy of segment 8 of the liver was performed. Pathological diagnosis revealed no residual tumor. If the metastases could be well controlled by systemic chemotherapy, hepatectomy for hepatic metastases of biliary tract cancer could be a treatment option.

  Aug. 2024, Gan to kagaku ryoho. Cancer & chemotherapy, 51(8) (8), 843 - 845, Japanese, Domestic magazine

  Scientific journal


• Association between tumor morphology and efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma.

  Nobuaki Ishihara, Shohei Komatsu, Keitaro Sofue, Eisuke Ueshima, Yoshihiko Yano, Yoshimi Fujishima, Jun Ishida, Masahiro Kido, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Hiroaki Yanagimoto, Hirochika Toyama, Yoshihide Ueda, Yuzo Kodama, Takamichi Murakami, Takumi Fukumoto

  AIM: The IMbrave150 trial revealed that atezolizumab plus bevacizumab (AtezoBv) showed a higher objective response rate (ORR) in patients with advanced hepatocellular carcinoma (HCC). Although conversion therapy after AtezoBv has been recently reported, markers predictive of its efficacy, particularly radiological imaging markers, have not yet been identified. The present study focused on tumor morphological appearance on radiological imaging and evaluated whether it could be associated with AtezoBv efficacy. METHODS: Ninety-five intrahepatic lesions in 74 patients who were given AtezoBv for advanced HCC were recruited for evaluation. The lesions were divided into two groups, simple nodular (SN group) and non-simple nodular (non-SN group), based on the gross morphology on pretreatment imaging, and retrospectively evaluated for treatment response and other relevant clinical outcomes. RESULTS: Assessing the size of individual tumors after treatment, waterfall plots showed that tumor shrinkage in the non-SN group including 56 lesions was higher than that in the SN group comprising 39 lesions. The ORR was significantly higher in the non-SN group (39.3% vs. 15.4%, p = 0.012). Additionally, the median time to nodular progression was longer in the non-SN group (21.0 months vs. 8.1 months, p = 0.119) compared to the SN group. Six patients with non-SN lesions underwent sequential local therapy. CONCLUSIONS: Atezolizumab plus bevacizumab may show increased therapeutic efficacy in patients with tumors with a higher potential for aggressive oncological behavior, such as non-SN lesions. Treatment strategies focusing on conversion therapy may be crucial in patients with non-SN lesions.

  Aug. 2024, Hepatology research : the official journal of the Japan Society of Hepatology, 54(8) (8), 773 - 780, English, International magazine

  Scientific journal


• Impact of bile leak on the prognosis of patients with hepatocellular carcinoma who have undergone liver resection.

  Hidetoshi Gon, Shohei Komatsu, Hirotoshi Soyama, Motofumi Tanaka, Kenji Fukushima, Takeshi Urade, Shinichi So, Toshihiko Yoshida, Keisuke Arai, Jun Ishida, Yoshihide Nanno, Daisuke Tsugawa, Hiroaki Yanagimoto, Hirochika Toyama, Masahiro Kido, Takumi Fukumoto

  PURPOSE: The impact of postoperative bile leak on the prognosis of patients with hepatocellular carcinoma who underwent liver resection is controversial. This study aimed to investigate the prognostic impact of bile leak for patients with hepatocellular carcinoma who underwent liver resection. METHODS: Patients with hepatocellular carcinoma who underwent liver resection between 2009 and 2019 at Kobe University Hospital and Hyogo Cancer Center were included. After propensity score matching between the bile leak and no bile leak groups, differences in 5-year recurrence-free and overall survival rates were evaluated using the Kaplan-Meier method. RESULTS: A total of 781 patients, including 43 with postoperative bile leak, were analyzed. In the matched cohort, 40 patients were included in each group. The 5-year recurrence-free survival rates after liver resection were 35% and 32% for the bile leak and no bile leak groups, respectively (P = 0.857). The 5-year overall survival rates were 44% and 54% for the bile leak and no bile leak groups, respectively (P = 0.216). CONCLUSION: Overall, bile leak may not have a profound negative impact on the prognosis of patients with hepatocellular carcinoma who have undergone liver resection.

  Jul. 2024, Langenbeck's archives of surgery, 409(1) (1), 233 - 233, English, International magazine

  Scientific journal


• Complete response to tremelimumab plus durvalumab treatment in hepatocellular carcinoma with a bile duct tumor thrombus: A case report.

  Nobuaki Ishihara, Shohei Komatsu, Masahiro Kido, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Toshihiko Yoshida, Keisuke Arai, Hiroaki Yanagimoto, Hirochika Toyama, Takumi Fukumoto

  Tremelimumab plus durvalumab (Dur/Tre) is the first-line treatment for advanced hepatocellular carcinoma (HCC) worldwide. The present report describes the case of a 68-year-old man diagnosed with advanced HCC and a bile duct tumor thrombus (BDTT) who achieved a complete response to Dur/Tre therapy. The BDTT progressed to the bifurcation of the left and right hepatic ducts. Over time, both the tumors and BDTT progressively decreased in size, and a complete response was confirmed using the Response Evaluation Criteria in Solid Tumors (version 1.1.) 6 months after treatment administration. Subsequently, immune-related adverse events, including type 1 diabetes mellitus and diabetic ketoacidosis, emerged, leading to treatment discontinuation. The patient was undergoing outpatient follow-up in a drug-free state with no signs of recurrence 290 days after the initial administration of Dur/Tre. Although long-term and meticulous observations are required, the present findings could influence the choice of systemic chemotherapy for advanced HCC.

  Jul. 2024, Oncology letters, 28(1) (1), 332 - 332, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Efficacy of S-1 Adjuvant Chemotherapy for Resected Biliary Tract Cancer: A Retrospective Propensity-Matched Analysis.

  Michihiko Yoshida, Hiroaki Yanagimoto, Daisuke Tsugawa, Masayuki Akita, Takeshi Urade, Yoshihide Nanno, Kenji Fukushima, Hidetoshi Gon, Shohei Komatsu, Sadaki Asari, Masahiro Kido, Hirochika Toyama, Tetsuo Ajiki, Takumi Fukumoto

  INTRODUCTION: Surgical resection is considered an effective cure for biliary tract cancer (BTC); however, the prognosis is unsatisfactory despite improved surgical techniques and perioperative management. The recurrence rate remains high even after curative resection. The efficacy of adjuvant chemotherapy in pancreatic and gastric cancers has been previously reported, and the feasibility of adjuvant therapy with S-1 has recently been reported in patients with resected BTC. We aimed to retrospectively investigate the effects of adjuvant chemotherapy with S-1 on resected advanced BTC. METHODS: We included data from 438 BTC patients who underwent resection between 2001 and 2020. After excluding patients with pTis-pT1 (n = 112) and other exclusion criteria, 266 patients were included in the analysis. RESULTS: After propensity score matching, 48 patients received S-1 adjuvant chemotherapy (S-1 group), and 48 patients received non-S1 adjuvant chemotherapy or underwent surgery alone (Non-S-1 group). The patients in the S-1 group had significantly better overall survival (OS) than those in the non-S-1 group (MST 51 vs 37 months, hazard ratio [HR]:.54, 95% confidence interval [CI]:.30-.98, P = .04). The S-1 group had a significantly better recurrence-free survival (RFS) than the non-S-1 group (94 vs 21 months, HR: .57, 95% CI: .33-.97, P = .03). Subgroup analyses for OS and RFS exhibited the benefits of S-1 in patients aged <75 years and in patients with primary sites of extrahepatic and perineural invasion and curability of R0. DISCUSSION: S-1 adjuvant therapy is promising for improving the postoperative survival of patients with resected advanced BTC, positive nerve invasion, and R0 resection.

  Jun. 2024, The American surgeon, 90(6) (6), 1279 - 1289, English, International magazine

  Scientific journal


• Spontaneous rupture of splenic hilar lymph node metastasis from hepatocellular carcinoma.

  Ryosuke Fujinaka, Takeshi Urade, Masahiro Kido, Shohei Komatsu, Hidetoshi Gon, Kenji Fukushima, Masato Komatsu, Hiroaki Yanagimoto, Hirochika Toyama, Takumi Fukumoto

  Spontaneous rupture of a primary hepatocellular carcinoma (HCC) is a frequently observed and fatal complication. However, the rupture of lymph node (LN) metastases from HCC is rare. A 79 year-old male with hepatitis B underwent three liver resections for HCC. Two years and 6 months after the last liver resection, enhanced computed tomography (CT) revealed a nodule with a diameter of 3 cm in the lower pole of the spleen. Splenic metastasis of HCC was suspected, and splenectomy was scheduled. During our hospital stay for a urinary tract infection before the scheduled operation, he complained of acute left-sided abdominal pain, and CT showed intra-abdominal hemorrhage due to rupture of the splenic tumor. Emergency splenectomy was performed, and the postoperative course was uneventful. Histopathological examination revealed a poorly differentiated HCC in the lower splenic pole lesion, which contained LN structures. The ruptured lesion was diagnosed as splenic hilar LN metastasis of HCC. Although laparoscopic partial liver resection was performed for intrahepatic recurrence, and atezolizumab plus bevacizumab therapy was administered for peritoneal metastases, the patient was alive 25 months after the splenectomy. Our case suggests that emergency surgery for LN metastatic rupture can achieve hemostasis and lead to improved survival outcomes.

  Jun. 2024, Clinical journal of gastroenterology, 17(3) (3), 557 - 562, English, Domestic magazine

  Scientific journal


• Optimal cutoff values of drain amylase for predicting pancreatic fistula are different between open and laparoscopic distal pancreatectomy.

  Jun Ishida, Hirochika Toyama, Sadaki Asari, Tadahiro Goto, Yoshihide Nanno, Toshihiko Yoshida, Shinichi So, Takeshi Urade, Kenji Fukushima, Hidetoshi Gon, Daisuke Tsugawa, Shohei Komatsu, Hiroaki Yanagimoto, Masahiro Kido, Takumi Fukumoto

  BACKGROUND: Drainage fluid amylase (DFA) is useful for predicting clinically relevant postoperative pancreatic fistula (CR-POPF) after distal pancreatectomy (DP). However, difference in optimal cutoff value of DFA for predicting CR-POPF between open DP (ODP) and laparoscopic DP (LDP) has not been investigated. This study aimed to identify the optimal cutoff values of DFA for predicting CR-POPF after ODP and LDP. METHODS: Data for 294 patients (ODP, n = 127; LDP, n = 167) undergoing DP at Kobe University Hospital between 2010 and 2021 were reviewed. Propensity score matching was performed to minimize treatment selection bias. Receiver operating characteristic (ROC) analysis was performed to determine the optimal cutoff values of DFA for predicting CR-POPF for ODP and LDP. Logistic regression analysis for CR-POPF was performed to investigate the diagnostic value of DFA on postoperative day (POD) three with identified cutoff value. RESULTS: In the matched cohort, CR-POPF rates were 24.7% and 7.9% after ODP and LDP, respectively. DFA on POD one was significantly lower after ODP than after LDP (2263 U/L vs 4243 U/L, p < 0.001), while the difference was not significant on POD three (543 U/L vs 1221 U/L, p = 0.171). ROC analysis revealed that the optimal cutoff value of DFA on POD one and three for predicting CR-POPF were different between ODP and LDP (ODP, 3697 U/L on POD one, 1114 U/L on POD three; LDP, 10564 U/L on POD one, 6020 U/L on POD three). Multivariate analysis showed that DFA on POD three with identified cutoff value was the independent predictor for CR-POPF both for ODP and LDP. CONCLUSIONS: DFA on POD three is an independent predictor for CR-POPF after both ODP and LDP. However, the optimal cutoff value for it is significantly higher after LDP than after ODP. Optimal threshold of DFA for drain removal may be different between ODP and LDP.

  May 2024, Surgical endoscopy, 38(5) (5), 2699 - 2708, English, International magazine

  Scientific journal


• Current Roles of Ramucirumab in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.

  Akira Koizumi, Shohei Komatsu, Satoshi Omiya, Yoshihiko Yano, Yoshimi Fujishima, Jun Ishida, Masahiro Kido, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Shinichi So, Toshihiko Yoshida, Keisuke Arai, Ryosuke Fujinaka, Yuhi Shimura, Hiroaki Yanagimoto, Hirochika Toyama, Yoshihide Ueda, Yuzo Kodama, Takumi Fukumoto

  BACKGROUND/AIM: The treatment algorithm for systemic therapies for advanced hepatocellular carcinoma (HCC) has changed dramatically; however, the therapeutic landscape for sequential second-line or later-line treatments, including ramucirumab, remains controversial. This study aimed to investigate the role of ramucirumab for treating HCC. PATIENTS AND METHODS: We retrospectively analyzed data from 17 patients with advanced HCC who received ramucirumab, and 8 of them who received lenvatinib re-administration after ramucirumab treatment failure. RESULTS: The median overall survival of 17 patients treated with ramucirumab was 11.5 months. The median ratios of the 1-month post-treatment α-fetoprotein (AFP) levels and albumin-bilirubin (ALBI) scores to the pre-treatment AFP levels and ALBI scores following ramucirumab treatment were 0.880 and 0.965, respectively. The median ratios of the 1-month post-treatment AFP and ALBI levels to the pre-treatment levels were 1.587 and 0.970 for mALBI grade 1/2a, and 1.313 and 0.936 for mALBI grade 2b/3, respectively. Six of the eight patients who received lenvatinib rechallenge treatment exhibited a decrease in AFP levels one month post-lenvatinib treatment. Deterioration of liver function 3 months post-lenvatinib treatment was noted in five of the eight patients who received lenvatinib rechallenge treatment after ramucirumab. CONCLUSION: Ramucirumab may be equally useful in patients with unresectable HCC who have poor liver function or whose liver function is aggravated by other therapies. Rechallenge treatment with lenvatinib after ramucirumab may be a valid treatment option for HCC.

  May 2024, Anticancer research, 44(5) (5), 2055 - 2061, English, International magazine

  Scientific journal


• The Albumin-bilirubin Grade as Prognostic Indicator for Recurrent Hepatocellular Carcinoma Needing Repeat Liver Resection.

  Hidetoshi Gon, Shohei Komatsu, Satoshi Omiya, Masahiro Kido, Kenji Fukushima, Takeshi Urade, Toshihiko Yoshida, Keisuke Arai, Jun Ishida, Yoshihide Nanno, Daisuke Tsugawa, Hiroaki Yanagimoto, Hirochika Toyama, Takumi Fukumoto

  BACKGROUND/AIM: This study aimed to evaluate the utility of the albumin-bilirubin grade for predicting the prognosis after repeat liver resection for patients with recurrent hepatocellular carcinoma. PATIENTS AND METHODS: Ninety patients with intrahepatic recurrent hepatocellular carcinoma who underwent repeat liver resection at our institution between 2005 and 2019 were retrospectively analyzed. Cox proportional-hazards regression models evaluated independent preoperative prognostic factors, including the albumin-bilirubin grade. Prognosis differences between patients with albumin-bilirubin grades 1 and 2 were analyzed using the Kaplan-Meier method. RESULTS: Cox proportional-hazards regression analysis revealed that albumin-bilirubin grade 2 (p=0.003) and early recurrence within one year from the initial surgery (p=0.001) were independently associated with poor recurrence-free survival, and albumin-bilirubin grade 2 (p=0.020) was independently associated with poor overall survival. The five-year recurrence-free (31% and 17%, respectively) and overall (86% and 60%, respectively) survival rates after repeat liver resection for patients with albumin-bilirubin grades 1 and 2 were significantly different between groups (both p=0.003). CONCLUSION: The albumin-bilirubin grade is useful for preoperatively predicting favorable survival rates after repeat liver resection for patients with recurrent hepatocellular carcinoma. Patients with an albumin-bilirubin grade 1 are better candidates for surgical treatment of recurrent hepatocellular carcinoma.

  May 2024, Anticancer research, 44(5) (5), 2031 - 2038, English, International magazine

  Scientific journal


• Utility of plasma D-dimer for diagnosis of venous thromboembolism after hepatectomy.

  Taiichiro Miyake, Hiroaki Yanagimoto, Daisuke Tsugawa, Masayuki Akita, Riki Asakura, Keisuke Arai, Toshihiko Yoshida, Shinichi So, Jun Ishida, Takeshi Urade, Yoshihide Nanno, Kenji Fukushima, Hidetoshi Gon, Shohei Komatsu, Sadaki Asari, Hirochika Toyama, Masahiro Kido, Tetsuo Ajiki, Takumi Fukumoto

  BACKGROUND: Venous thromboembolism (VTE) is a potentially fatal complication of hepatectomy. The use of postoperative prophylactic anticoagulation in patients who have undergone hepatectomy is controversial because of the risk of postoperative bleeding. Therefore, we hypothesized that monitoring plasma D-dimer could be useful in the early diagnosis of VTE after hepatectomy. AIM: To evaluate the utility of monitoring plasma D-dimer levels in the early diagnosis of VTE after hepatectomy. METHODS: The medical records of patients who underwent hepatectomy at our institution between January 2017 and December 2020 were retrospectively analyzed. Patients were divided into two groups according to whether or not they developed VTE after hepatectomy, as diagnosed by contrast-enhanced computed tomography and/or ultrasonography of the lower extremities. Clinicopathological factors, including demographic data and perioperative D-dimer values, were compared between the two groups. Receiver operating characteristic curve analysis was performed to determine the D-dimer cutoff value. Univariate and multivariate analyses were performed using logistic regression analysis to identify significant predictors. RESULTS: In total, 234 patients who underwent hepatectomy were, of whom (5.6%) were diagnosed with VTE following hepatectomy. A comparison between the two groups showed significant differences in operative time (529 vs 403 min, P = 0.0274) and blood loss (530 vs 138 mL, P = 0.0067). The D-dimer levels on postoperative days (POD) 1, 3, 5, 7 were significantly higher in the VTE group than in the non-VTE group. In the multivariate analysis, intraoperative blood loss of > 275 mL [odds ratio (OR) = 5.32, 95% confidence interval (CI): 1.05-27.0, P = 0.044] and plasma D-dimer levels on POD 5 ≥ 21 μg/mL (OR = 10.1, 95%CI: 2.04-50.1, P = 0.0046) were independent risk factors for VTE after hepatectomy. CONCLUSION: Monitoring of plasma D-dimer levels after hepatectomy is useful for early diagnosis of VTE and may avoid routine prophylactic anticoagulation in the postoperative period.

  Jan. 2024, World journal of clinical cases, 12(2) (2), 276 - 284, English, International magazine

  Scientific journal


• A Novel Method Using Gadolinium-Ethoxybenzyl Diethylenetriamine Pentaacetate Acid-Enhanced Magnetic Resonance Imaging for Predicting Post-Hepatectomy Liver Failure in Hepatocellular Carcinoma Patients with a Major Portal Vein Tumor Thrombus.

  Kosuke Nishio, Shohei Komatsu, Keitaro Sofue, Masahiro Kido, Kaori Kuramitsu, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Hiroaki Yanagimoto, Hirochika Toyama, Takumi Fukumoto

  INTRODUCTION: The usefulness of gadolinium-ethoxybenzyl diethylenetriamine pentaacetate acid-enhanced magnetic resonance imaging (EOB-MRI) in assessing the functional future remnant liver volume (fFRLV) to predict post-hepatectomy liver failure (PHLF) has been previously reported. Herein, we evaluated the efficacy of this technique in patients with hepatocellular carcinoma (HCC) with a major portal vein tumor thrombus (PVTT). METHODS: This study included 21 patients with PVTT in the ipsilateral first-order branch (Vp3) and 30 patients with PVTT in the main trunk/contralateral branch (Vp4). To evaluate fFRLV, the signal intensity (SI) of the remnant liver was determined on T1-weighted images, using both conventional and newly developed methods. The fFRLV was calculated using the SI of the remnant liver and muscle, remnant liver volume, and body surface area. Preoperative factors predicting PHLF (≥grade B) in HCC patients with Vp3/4 PVTT were evaluated. RESULTS: In the Vp3 group, we found fFRLV area under the receiver-operating characteristic curves (AUCs) above 0.70 (AUC = 0.875, 0.750) using EOB-MRI results calculated using either the plot or whole method. None of the parameters in the Vp4 group had an AUC greater than 0.70. CONCLUSION: The fFRLV calculated by EOB-MRI using the whole method can be as useful as the conventional method in predicting PHLF (≥grade B) for HCC patients with Vp3 PVTT.

  2024, Digestive surgery, 41(1) (1), 30 - 36, English, International magazine

  Scientific journal


• [A Case of Ampullary Carcinoma with Celiac Axis Stenosis That Underwent Pancreaticoduodenectomy and Arterial Reconstruction].

  Yuki Okazoe, Daisuke Tsugawa, Hiroaki Yanagimoto, Masayuki Akita, Shinichi So, Jun Ishida, Yoshihide Nanno, Takeshi Urade, Kenji Fukushima, Hidetoshi Gon, Shohei Komatsu, Sadaki Asari, Hirochika Toyama, Masahiro Kido, Takumi Fukumoto

  A 72-year-old male patient presented with obstructive jaundice and was diagnosed with ampullary carcinoma. Contrast- enhanced computed tomography(CT)showed stenosis of the common hepatic artery and dilatation of the pancreaticoduodenal arcade(PDA)due to celiac axis stenosis(CAS)at the origin, suggesting that hepatic artery blood flow was supplied from the superior mesenteric artery via the PDA. Since calcification of the arterial wall was observed at the origin of the celiac artery(CA), the cause of the CAS was diagnosed as atherosclerotic. An intraoperative gastroduodenal artery(GDA) clamp test showed no obvious decrease in hepatic arterial blood flow. However, because of concerns about the postoperative patency of the CA, an inferior pancreaticoduodenal artery-GDA bypass using the left great saphenous vein and subtotal stomach-preserving pancreaticoduodenectomy were performed. The postoperative course was uneventful. When pancreaticoduodenectomy is performed in patients with atherosclerotic CAS, this arterial reconstruction method can be considered as an option.

  Dec. 2023, Gan to kagaku ryoho. Cancer & chemotherapy, 50(13) (13), 1534 - 1536, Japanese, Domestic magazine

  Scientific journal


• Risk Factors for Recurrence of Cholangitis After Pancreaticoduodenectomy and Comparison of Stents in Hepaticojejunostomy.

  Hirotaka Fukuoka, Hirochika Toyama, Takuya Mizumoto, Jun Ishida, Sadaki Asari, Tadahiro Goto, Yoshihide Nanno, Takeshi Urade, Kenji Fukushima, Hidetoshi Gon, Daisuke Tsugawa, Shohei Komatsu, Kaori Kuramitsu, Hiroaki Yanagimoto, Masahiro Kido, Tetsuo Ajiki, Takumi Fukumoto

  BACKGROUND: Postoperative cholangitis is a common complication of pancreaticoduodenectomy. Frequent cholangitis impairs patients' quality of life after pancreaticoduodenectomy. However, the risk factors for recurrence of cholangitis remain unclear. Hence, this retrospective study aimed to identify risk factors for recurrence of cholangitis after pancreaticoduodenectomy. METHODS: The medical records of patients who underwent pancreaticoduodenectomy between 2015 and 2019 in our institution were retrospectively reviewed. At least two episodes of cholangitis a year after pancreaticoduodenectomy were defined as 'recurrence of cholangitis' in the present study. Univariate and multivariate analyses were performed. RESULTS: The recurrence of cholangitis occurred in 40 of 207 patients (19.3%). Multivariate analysis revealed that internal stent (external, RR: 2.16, P = 0.026; none, RR: 4.76, P = 0.011), firm pancreas (RR: 2.61, P = 0.021), constipation (RR: 3.49, P = 0.008), and postoperative total bilirubin>1.7 mg/dL (RR: 2.94, P = 0.006) were risk factors of recurrence of cholangitis. Among patients with internal stents (n = 54), those with remnant stents beyond 5 months had more frequent recurrence of cholangitis (≥5 months, 75%; <5 months, 30%). CONCLUSIONS: Internal stents, firm pancreas, constipation, and postoperative high bilirubin levels are risk factors for cholangitis recurrence after pancreaticoduodenectomy. In addition, the long-term implantation of internal stents may trigger cholangitis recurrence.

  Oct. 2023, World journal of surgery, 47(10) (10), 2499 - 2506, English, International magazine

  Scientific journal


• The Usefulness of Total Tumor Volume as a Prognostic Factor and in Selecting the Optimal Treatment Strategy of Chemotherapeutic Intervention in Patients with Colorectal Liver Metastases.

  Yuhi Shimura, Shohei Komatsu, Yoshiaki Nagatani, Yohei Funakoshi, Keitaro Sofue, Masahiro Kido, Kaori Kuramitsu, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Shinichi So, Hiroaki Yanagimoto, Hirochika Toyama, Hironobu Minami, Takumi Fukumoto

  BACKGROUND: Few reports have discussed the association between total tumor volume (TTV) and prognosis in patients with colorectal liver metastases (CRLM). The present study aimed to evaluate the usefulness of TTV for predicting recurrence-free survival and overall survival (OS) in patients receiving initial hepatic resection or chemotherapy, and to investigate the value of TTV as an indicator for optimal treatment selection for patients with CRLM. PATIENTS AND METHODS: This retrospective cohort study included patients with CRLM who underwent hepatic resection (n = 93) or chemotherapy (n = 78) at the Kobe University Hospital. TTV was measured using 3D construction software and computed tomography images. RESULTS: A TTV of 100 cm3 has been previously reported as a significant cut-off value for predicting OS of CRLM patients receiving initial hepatic resection. For patients receiving hepatic resection, the OS for those with a TTV ≥ 100 cm3 was significantly reduced compared with those with a TTV < 100 cm3. For patients receiving initial chemotherapy, there were no significant differences between the groups divided according to TTV cut-offs. Regarding OS of patients with TTV ≥ 100 cm3, there was no significant difference between hepatic resection and chemotherapy (p = 0.160). CONCLUSIONS: TTV can be a predictive factor of OS for hepatic resection, unlike for initial chemotherapy treatment. The lack of significant difference in OS for CRLM patients with TTV ≥ 100 cm3, regardless of initial treatment, suggests that chemotherapeutic intervention preceding hepatic resection may be indicated for such patients.

  Jun. 2023, Annals of surgical oncology, 30(11) (11), 6603 - 6610, English, International magazine

  Scientific journal


• Transarterial chemoembolization for liver metastases of a pancreatic neuroendocrine neoplasm: a single-center experience.

  Yoshihide Nanno, Hirochika Toyama, Eisuke Ueshima, Keitaro Sofue, Ippei Matsumoto, Jun Ishida, Takeshi Urade, Kenji Fukushima, Hidetoshi Gon, Daisuke Tsugawa, Shohei Komatsu, Kaori Kuramitsu, Tadahiro Goto, Sadaki Asari, Hiroaki Yanagimoto, Masahiro Kido, Tetsuo Ajiki, Takumi Fukumoto

  Transarterial chemoembolization (TACE) is performed for pancreatic neuroendocrine tumor (PanNEN) liver metastases; however, the safety and efficacy of TACE procedures, especially for patients who have undergone previous pancreatic surgery, have not been established. We reviewed 48 TACE procedures (1-6 procedures/patient) performed on 11 patients with PanNEN liver metastases, including 16 TACE procedures (4-6 procedures/patient) for 3 patients with a history of biliary-enteric anastomosis. The overall tumor objective response rate was 94%. The incidence of Clavien‒Dindo grade ≥ 2 complications was 1/16 (6%) and 1/32 (3%), and the median time to untreatable progression was 31 (14-41) and 27 (2-60) months among patients with and without a history of biliary-enteric anastomosis, respectively. Although validation is needed in future studies, our experiences have shown that TACE treatment is a viable treatment option for PanNEN liver metastases, even after biliary-enteric anastomosis with experienced teams and careful patient follow-up.

  Jun. 2023, Surgery today, 53(12) (12), 1396 - 1400, English, Domestic magazine

  Scientific journal


• Advantages of the Laparoscopic Approach for the Initial Operation in Patients who Underwent Repeat Hepatectomy.

  Hidetoshi Gon, Shohei Komatsu, Masahiro Kido, Kenji Fukushima, Takeshi Urade, Shinichi So, Toshihiko Yoshida, Keisuke Arai, Jun Ishida, Yoshihide Nanno, Daisuke Tsugawa, Hiroaki Yanagimoto, Hirochika Toyama, Takumi Fukumoto

  BACKGROUND: Less intra-abdominal adhesions are expected following laparoscopic surgery. Although an initial laparoscopic approach for primary liver tumors may have advantages in patients who require repeat hepatectomies for recurrent liver tumors, this has not been sufficiently investigated. METHODS: Patients who underwent repeat hepatectomies for recurrent liver tumors at our hospital between 2010 and 2022 were retrospectively analyzed. Of 127 patients, 76 underwent laparoscopic repeat hepatectomy (LRH), of whom 34 patients initially underwent laparoscopic hepatectomy (L-LRH) and 42, open hepatectomy (O-LRH). Fifty-one patients underwent open hepatectomy as both the initial and second operation (O-ORH). We analyzed surgical outcomes between L-LRH and O-LRH groups and between L-LRH and O-ORH groups using propensity-matching analysis for each pattern. RESULTS: Twenty-one patients each were included in L-LRH and O-LRH propensity-matched cohorts. The L-LRH group had a lower rate of postoperative complications than the O-LRH group (0 vs 19%, P = 0.036). When we compared surgical outcomes between L-LRH and O-ORH groups in another matched cohort with 18 patients in each group, in addition to the lower rate of postoperative complications, the L-LRH group had additional favorable surgical outcomes including shorter operation time and lower blood loss volume than the O-ORH group (291 vs 368 min, P = 0.037 and 10 vs 485 mL, P < 0.0001). CONCLUSIONS: An initial laparoscopic approach would be favorable for patients undergoing repeat hepatectomies, as it leads to lower risk of postoperative complications. Compared with O-ORH, the advantage of the laparoscopic approach may be enhanced when it is repeatedly adopted.

  Jun. 2023, Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 27(8) (8), 1621 - 1631, English, International magazine

  Scientific journal


• Prognostic Impact of Malnutrition Diagnosed by the GLIM Criteria for Resected Extrahepatic Cholangiocarcinoma.

  Yuki Okazoe, Hiroaki Yanagimoto, Daisuke Tsugawa, Masayuki Akita, Riki Asakura, Satoshi Omiya, Takeshi Urade, Yoshihide Nanno, Kenji Fukushima, Hidetoshi Gon, Shohei Komatsu, Kaori Kuramitsu, Tadahiro Goto, Sadaki Asari, Hirochika Toyama, Masahiro Kido, Tetsuo Ajiki, Takumi Fukumoto

  BACKGROUND/AIM: Recently, the Global Leadership Initiative on Malnutrition (GLIM), which includes the world's leading clinical nutrition societies, proposed the first global diagnostic criteria for malnutrition. However, the association between malnutrition diagnosed by the GLIM criteria and prognosis in patients with resected extrahepatic cholangiocarcinoma (ECC) remains unknown. This study aimed to investigate the predictive validity of the GLIM criteria for the prognosis of patients with resected ECC. PATIENTS AND METHODS: Between 2000 and 2020, 166 patients who underwent curative-intent resection for ECC were retrospectively analyzed. Prognostic significance of preoperative malnutrition diagnosed by the GLIM criteria was investigated using a multivariate Cox proportional hazards model. RESULTS: Eighty-five (51.2%) and 46 (27.7%) patients were diagnosed with moderate and severe malnutrition, respectively. Increased malnutrition severity tended to be correlated with increased lymph node metastasis rate (p-for-trend=0.0381). The severe malnutrition group had worse 1-, 3-, and 5-year overall survival rates than the normal (without malnutrition) group (82.2% vs. 91.2%, 45.6% vs. 65.1%, 29.3% vs. 61.5%, respectively, p=0.0159). In multivariate analysis, preoperative severe malnutrition was an independent predictor for poor prognosis (hazard ratio=1.68, 95% confidence interval=1.06-2.66, p=0.0282), along with intraoperative blood loss >1,000 ml, lymph node metastasis, perineural invasion, and curability. CONCLUSION: Severe preoperative malnutrition diagnosed by the GLIM criteria was associated with poor prognosis in patients who underwent curative-intent resection for ECC.

  May 2023, Anticancer research, 43(5) (5), 2299 - 2308, English, International magazine

  Scientific journal


• Factors Predicting Over-Time Weight Increase After Liver Transplantation: A Retrospective Study.

  Yuhi Shimura, Kaori Kuramitsu, Masahiro Kido, Shohei Komatsu, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Shinichi So, Toshihiko Yoshida, Keisuke Arai, Daisuke Tsugawa, Tadahiro Goto, Sadaki Asari, Hiroaki Yanagimoto, Hirochika Toyama, Tetsuo Ajiki, Takumi Fukumoto

  BACKGROUND: Post-transplantation weight control is important for long-term outcomes; however, few reports have examined postoperative weight change. This study aimed to identify perioperative factors contributing to post-transplantation weight change. METHODS: Twenty-nine patients who underwent liver transplantation between 2015 and 2019 with an overall survival of >3 years were analyzed. RESULTS: The median age, model for end-stage liver disease score, and preoperative body mass index (BMI) of the recipients were 57, 25, and 23.7, respectively. Although all but one recipient lost weight, the percentage of recipients who gained weight increased to 55% (1 month), 72% (6 months), and 83% (12 months). Among perioperative factors, recipient age ≤50 years and BMI ≤25 were identified as risk factors for weight gain within 12 months (P < .05), and patients with age ≤50 years or BMI ≤25 recipients gained weight more rapidly (P < .05). The recovery time of serum albumin level ≥4.0 mg/dL was not statistically different between the 2 groups. The weight change during the first 3 years after discharge was represented by an approximately straight line, with 18 and 11 recipients showing a positive and negative slope, respectively. Body mass index ≤23 was identified as a risk factor for a positive slope of weight gain (P <.05). CONCLUSIONS: Although postoperative weight gain implies recovery after transplantation, recipients with a lower preoperative BMI should strictly manage body weight as they may be at higher risk of rapid weight increase.

  Apr. 2023, Transplantation proceedings, 55(4) (4), 924 - 929, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• 横隔膜腹腔側に発生したsolitary fibrous tumorの1例

  上田 泰弘, 味木 徹夫, 浅利 貞毅, 柳本 泰明, 津川 大介, 秋田 真之, 朝倉 力, 三宅 泰一郎, 南野 佳英, 浦出 剛史, 福島 健司, 権 英寿, 小松 昇平, 蔵満 薫, 後藤 直大, 外山 博近, 木戸 正浩, 福本 巧

  72歳女性。右季肋部痛を主訴に前医を受診し、右横隔膜原発の腫瘍を指摘され、精査加療目的で当院へ紹介となった。腹部CT検査では右横隔膜と連続した9cm大で、不均一な造影効果を伴う境界明瞭な腫瘤が認められた。また、腹部MRI検査ではT1強調画像にて筋組織と同程度の低信号ほか、T2強調画像にて高信号を呈する腫瘤が認められた。以上、これらの所見を踏まえて、針生検を施行したところ、採取されたのは壊死組織のみで、診断には困難であった。そこで、右横隔膜原発の腫瘍とみなし、開腹下に腫瘍を切除した結果、病理組織学的に右横隔膜腹腔側に発生したsolitary fibrous tumorと確定診断された。術後1年経過現在、無再発生存中である。

  兵庫県外科医会, Mar. 2023, 兵庫県外科医会会誌, 57, 13 - 15, Japanese


• Assessment of serum and drain fluid bilirubin concentrations in liver transplantation patients.

  Hirotoshi Soyama, Kaori Kuramitsu, Masahiro Kido, Shohei Komatsu, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Shinichi So, Yoshihide Nanno, Daisuke Tsugawa, Tadahiro Goto, Hiroaki Yanagimoto, Sadaki Asari, Hirochika Toyama, Tetsuo Ajiki, Takumi Fukumoto

  BACKGROUND: Bile leakage is a major complication after liver transplantation and remains as a significant source of morbidity and mortality. In 2011, the International Study Group of Liver Surgery (ISGLS) defined bile leakage as a drain/serum bilirubin ratio ≥3. However, to our knowledge there is no literature assessing serum and drain bilirubin concentrations after liver transplantation. The aim of this study was to describe the natural postoperative changes in serum and drain fluid bilirubin concentrations in patients after liver transplantation. METHODS: We included 32 patients who underwent liver transplantation at Kobe University Hospital from January 2007 to December 2020. We enrolled 34 living donors who had no complications as the control group. RESULTS: The recipient serum total/direct bilirubin concentration were higher compared with the donors from postoperative day (POD) 1 to 5 with a statistical difference (P < .05). The recipient drain/serum total bilirubin ratio was lower than donors on POD 3 (0.89 ± 0.07 vs 1.53 ± 0.07: P < .0001), which was also confirmed by the recipient drain/serum direct bilirubin ratio (0.64 ± 0.10 vs 1.18 ± 0.09: P < .0001). On POD 3, the drain fluid volume (647.38 ± 89.47 vs 113.43 ± 86.8 mL: P < .001) and serum total bilirubin concentration (6.73 ± 0.61 vs 1.23 ± 0.60 mg/dL: P < .001) was higher in the recipients than in donors. Categorized in 2 groups, the higher drain fluid volume and bilirubin concentration recipients showed lower drain/serum total bilirubin ratio compared with the other group (P = .03) CONCLUSION: The drain/serum bilirubin ratio in the transplanted patients could be calculated lower compared with the hepatectomy patients because of high drain fluid volume and hyperbilirubinemia. Great care should be taken when assessing the bile leakage in liver transplant recipients using the ISGLS definition.

  Jan. 2023, Transplantation proceedings, 55(1) (1), 184 - 190, English, International magazine

  Scientific journal


• Laparoscopic Medial-to-Lateral Approach for the Resection of Hepatocellular Carcinoma Located at the Spiegel Lobe of the Liver.

  Hidetoshi Gon, Masahiro Kido, Shohei Komatsu, Kenji Fukushima, Takeshi Urade, Yoshihide Nanno, Daisuke Tsugawa, Hiroaki Yanagimoto, Hirochika Toyama, Takumi Fukumoto

  BACKGROUND: Laparoscopic caudate lobe resection is a challenging procedure. Several researchers have reported the safety of laparoscopic liver resections;1.Transl Gastroenterol Hepatol. 1:56;2.Asian J Endosc Surg. 12:232-236;3.Ann Surg Oncol. 26:2980; however, a standardized procedure has not yet been established. Herein, we present a video showing laparoscopic Spiegel lobectomy in a patient with 6-cm hepatocellular carcinoma (HCC) using a novel approach. PATIENT AND METHODS: A 63-year-old man with a caudate lobe HCC was referred to our hospital. Computed tomography showed a 5 × 6 cm2 HCC located in the Spiegel lobe, which profoundly displaced the inferior vena cava (IVC) to the lower right side, and mobilization of the Spiegel lobe was considered difficult. To perform the dissection between the Siegel lobe and IVC safely, we performed parenchymal transection along the ventral side of the IVC initially. The Spiegel lobe was then dislocated to the left side of the IVC. We dissected the left lateral side of the IVC, including the proper hepatic vein draining the caudate lobe and the left IVC ligament with a safe operative field, and successfully removed the Spiegel lobe with large HCC. RESULTS: The operation time was 383 min. The blood loss was 10 mL. The patient was discharged on the seventh postoperative day without any complications. Histopathological examination revealed well-differentiated HCC with a negative surgical margin. CONCLUSIONS: Laparoscopic medial-to-lateral approach with initial parenchymal transection at the medial side of the Spiegel lobe followed by dissection of the left lateral side of the IVC is considered as a safe and effective procedure for large tumors in the Spiegel lobe.

  Jan. 2023, Annals of surgical oncology, 30(1) (1), 381 - 382, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Safe Laparoscopic Resection of Hepatocellular Carcinoma in the Spiegel Lobe of the Liver Using a Medial-to-Lateral Approach.

  Hidetoshi Gon, Masahiro Kido, Shohei Komatsu, Kenji Fukushima, Takeshi Urade, Yoshihide Nanno, Daisuke Tsugawa, Hiroaki Yanagimoto, Hirochika Toyama, Takumi Fukumoto

  Jan. 2023, Annals of surgical oncology, 30(1) (1), 383 - 383, English, International magazine

  Scientific journal


• Potential Role of Surgical Resection for Gallbladder Cancer in Elderly Patients.

  Yasuhiro Ueda, Hiroaki Yanagimoto, Tetsuo Ajiki, Daisuke Tsugawa, Riki Asakura, Takeshi Urade, Yoshihide Nanno, Kenji Fukushima, Hidetoshi Gon, Shohei Komatsu, Kaori Kuramitsu, Tadahiro Goto, Sadaki Asari, Hirochika Toyama, Masahiro Kido, Takumi Fukumoto

  INTRODUCTION: With the aging of the population in Japan, gallbladder cancer (GBC) in the elderly is increasing. However, the available clinical data are limited, and the optimal treatment is still controversial. The aim of this study was to evaluate the benefit of surgical resection in GBC patients ≥75 years of age. METHODS: A retrospective single center analysis of patients who had undergone surgical resection for GBC between 2000 and 2019 was carried out. Patients aged ≥75 years (elderly group, n = 24) or <75 years (younger group, n = 50) were compared. RESULTS: Both younger and elderly patients exhibited similar clinicopathological characteristics, but comorbidity in the latter was significantly greater, as was the frequency of less invasive surgery. Nonetheless, the incidence of postoperative complications was similar in elderly and younger patients. The proportion of patients receiving adjuvant chemotherapy was lower in the elderly. Overall survival of elderly and younger patients was not significantly different (65.0 vs 62.4% at 5 years, P = .600). In multivariate analysis, residual tumor status but not age was an independent prognostic factor. DISCUSSION: This study demonstrated that appropriate surgical treatment of elderly GBC patients was safe and effective, despite their having more comorbidities and lower rates of adjuvant chemotherapy than younger patients.

  Nov. 2022, The American surgeon, 89(12) (12), 31348221136570 - 31348221136570, English, International magazine

  Scientific journal


• 進行肝細胞癌におけるconversion surgeryの妥当性

  石原 伸朗, 小松 昇平, 矢野 嘉彦, 木戸 正浩, 蔵満 薫, 権 英寿, 福島 健司, 浦出 剛史, 宗 慎一, 山本 淳史, 藤島 佳未, 石田 淳, 津川 大介, 後藤 直大, 浅利 貞毅, 柳本 泰明, 外山 博近, 上田 佳秀, 味木 徹夫, 福本 巧

  (株)医薬情報研究所, Nov. 2022, 新薬と臨牀, 71(11) (11), 1234 - 1234, Japanese


• 進行肝細胞癌におけるconversion surgeryの妥当性

  石原 伸朗, 小松 昇平, 矢野 嘉彦, 木戸 正浩, 蔵満 薫, 権 英寿, 福島 健司, 浦出 剛史, 宗 慎一, 山本 淳史, 藤島 佳未, 石田 淳, 津川 大介, 後藤 直大, 浅利 貞毅, 柳本 泰明, 外山 博近, 上田 佳秀, 味木 徹夫, 福本 巧

  (株)医薬情報研究所, Nov. 2022, 新薬と臨牀, 71(11) (11), 1234 - 1234, Japanese


• Standardization of laparoscopic anatomic liver resection of segment 2 by the Glissonean approach.

  Takeshi Urade, Masahiro Kido, Kaori Kuramitsu, Shohei Komatsu, Hidetoshi Gon, Kenji Fukushima, Shinichi So, Takuya Mizumoto, Yoshihide Nanno, Daisuke Tsugawa, Tadahiro Goto, Sadaki Asari, Hiroaki Yanagimoto, Hirochika Toyama, Tetsuo Ajiki, Takumi Fukumoto

  BACKGROUND: Anatomic liver resection (ALR) has been established to eliminate the tumor-bearing hepatic region with preservation of the remnant liver volume for liver malignancies. Recently, laparoscopic ALR has been widely applied; however, there are few reports on laparoscopic segmentectomy 2. This study aimed to present the standardization of laparoscopic segmentectomy 2 with surgical outcomes. METHODS: This study included seven patients who underwent pure laparoscopic segmentectomy 2 by the Glissonean approach from January 2020 to December 2021. Four of them had hepatocellular carcinoma, two had colorectal liver metastasis, and one had hepatic angiomyolipoma, which was preoperatively diagnosed with hepatocellular carcinoma. In all patients, preoperative three-dimensional (3D) simulation images from dynamic CT were reconstructed using a 3D workstation. The layer between the hepatic parenchyma and the Glissonean pedicle of segment 2 (G2) was dissected to encircle the root of G2. After clamping or ligation of the G2, 2.5 mg of indocyanine green was injected intravenously to identify the boundaries between segments 2 and 3 with a negative staining method under near-infrared light. Parenchymal transection was performed from the caudal side to the cranial side according to the demarcation on the liver surface, and the left hepatic vein was exposed on the cut surface if possible. RESULTS: The mean operative time for all patients was 281 min. The mean blood loss was 37 mL, and no transfusion was necessary. Estimated liver resection volumes significantly correlated with actual liver resection volumes (r = 0.61, P = 0.035). After the operation, one patient presented with asymptomatic deep venous and pulmonary thrombosis, which was treated with anticoagulant therapy. The mean length of hospital stay was 8.9 days. CONCLUSION: Laparoscopic segmentectomy 2 by the Glissonean approach is a feasible and safe procedure with the preservation of the nontumor-bearing segment 3 for liver tumors in segment 2.

  Nov. 2022, Surgical endoscopy, 36(11) (11), 8600 - 8606, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Rechallenge With Lenvatinib After Atezolizumab Plus Bevacizumab Treatment for Hepatocellular Carcinoma.

  Shohei Komatsu, Yoshihiko Yano, Masahiro Kido, Kaori Kuramitsu, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Shinichi So, Atsushi Yamamoto, Tadahiro Goto, Hiroaki Yanagimoto, Hirochika Toyama, Yoshihide Ueda, Yuzo Kodama, Takumi Fukumoto

  BACKGROUND/AIM: Atezolizumab plus bevacizumab and lenvatinib are the key drugs in the current systemic chemotherapeutic regimen for hepatocellular carcinoma (HCC). Studies have reported the potential effectiveness of lenvatinib introduction after an atezolizumab plus bevacizumab treatment; however, the therapeutic effectiveness of a lenvatinib rechallenge after an atezolizumab plus bevacizumab treatment remains unclear. PATIENTS AND METHODS: Thirteen consecutive patients who were rechallenged with lenvatinib after clinical failure following treatments with lenvatinib and atezolizumab plus bevacizumab were included. A comparative study was conducted on the duration and treatment efficacy of the first and second lenvatinib treatments and on the pre- and post-treatment liver function. RESULTS: The median ratios of the 1-month post-treatment alpha-fetoprotein (AFP) levels to the pretreatment AFP levels were 0.750 and 0.667 for the first and second lenvatinib treatments, respectively, without significant difference (p=0.9327). Meanwhile, the median ratios of the 1-month post-treatment albumin-bilirubin (ALBI) scores to the pretreatment ALBI scores were 1.063 and 0.827 for the first and second lenvatinib treatments, respectively, with significant difference (p=0.015). The median duration of the second lenvatinib treatment was significantly shorter than that of the first lenvatinib treatment [2.8 months (range=0.9-4.7 months) vs. 8.7 months (range=3.1-29.7 months)]. CONCLUSION: Lenvatinib re-administration after atezolizumab plus bevacizumab treatment can act as a double-edged sword, as it exerts an anti-tumor effect while being associated with potential liver function deterioration. However, this treatment sequence can be useful, and requires careful monitoring of the transitions in the liver function and the patient's performance status.

  Nov. 2022, Anticancer research, 42(11) (11), 5479 - 5486, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Suitability of Laparoscopic Liver Resection of Segment VII: a Retrospective Two-Center Study.

  Hidetoshi Gon, Hisoka Yamane, Toshihiko Yoshida, Masahiro Kido, Motofumi Tanaka, Kaori Kuramitsu, Shohei Komatsu, Kenji Fukushima, Takeshi Urade, Shinichi So, Yoshihide Nanno, Daisuke Tsugawa, Tadahiro Goto, Hiroaki Yanagimoto, Hirochika Toyama, Takumi Fukumoto

  BACKGROUND: Resecting liver tumors located in Couinaud's segment VII is challenging; the efficacy and safety of laparoscopic liver resection for segment VII lesions compared to open liver resection remain unclear. METHODS: Medical records of 84 patients who underwent liver resection of segment VII at Kobe University Hospital and Hyogo Cancer Center between 2010 and 2021 were retrospectively analyzed. Surgical outcomes were compared between laparoscopic liver resection and open liver resection groups using propensity matching analysis. RESULTS: Thirty-one and 53 patients underwent laparoscopic liver resection and open liver resection, respectively. After propensity matching, 29 patients were included in each group. The laparoscopic liver resection group had a significantly longer operation time (407 vs. 305 min, P = 0.002), lower blood loss (100 vs. 230 mL, P = 0.004), and higher postoperative alanine aminotransferase levels (436 vs. 252 IU/L, P = 0.008) than the open liver resection group. In patients with liver cirrhosis, the proportion of patients with postoperative liver-specific complications was higher in the laparoscopic liver resection group than in the open liver resection group (57% vs 11%, P = 0.049), although there was no significant difference in postoperative liver-specific complication rates between the groups in patients without liver cirrhosis. CONCLUSIONS: For liver resection of segment VII, laparoscopic liver resection led to higher postoperative liver damage than open liver resection. Open liver resection may be better for patients with liver cirrhosis to avoid postoperative liver-specific complications. Laparoscopic liver resection could be an acceptable procedure for patients without liver cirrhosis, with some merits such as less blood loss.

  Jun. 2022, Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 26(11) (11), 2274 - 2281, English, International magazine

  Scientific journal


• Impact of Hepatectomy for Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombus.

  Shohei Komatsu, Masahiro Kido, Kaori Kuramitsu, Daisuke Tsugawa, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Hiroaki Yanagimoto, Hirochika Toyama, Takumi Fukumoto

  BACKGROUND: Optimal treatment strategies for advanced hepatocellular carcinoma (HCC) with macroscopic portal vein tumor thrombus (PVTT) remain controversial. Therefore, this study aimed to assess the impact and predictive factors of hepatectomy for HCC with macroscopic PVTT. METHODS: This study included 100 patients who presented with intraoperatively confirmed PVTT extending to the first portal branch (Vp3), main portal trunk, or opposite-side portal branch (Vp4) between June 2000 and December 2019. Their postoperative outcomes and predictive factors for survival were evaluated. RESULTS: Of the 100 patients, 37 (37%) and 63 (63%) had Vp3 and Vp4 PVTTs, respectively. Moreover, 42 (42%) and 58 (58%) patients underwent R0/1 and R2 hepatectomies, respectively. The median survival time (MST) of all patients with Vp3/4 PVTT was 14.5 months; the 1- and 3-year overall survival rates were 59.6 and 16.8%, respectively. The MSTs of patients with Vp3 and Vp4 PVTTs were 16.1 and 14.3 months, respectively (P = 0.7098). The MSTs of patients who underwent R0/1 and R2 hepatectomies were 14.3 and 14.9 months, respectively (P = 0.3831). All assessed tumor factors (including the Vp status [Vp3 or Vp4], type of resection [R0/1 or R2], intrahepatic maximal tumor size, intrahepatic tumor number, and the existence of extrahepatic metastasis) did not influence the overall survival significantly. CONCLUSIONS: Tumor factors, such as the presence of a Vp3/4 PVTT, have a strong impact on survival; however, other multiple tumor factors have a limited impact. Hepatectomy can be an effective treatment option for HCC with Vp3/4 PVTT, and its indications should be considered.

  Apr. 2022, Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 26(4) (4), 822 - 830, English, International magazine

  Scientific journal


• Prognostic impact of inflammation-based scores for extrahepatic cholangiocarcinoma.

  Riki Asakura, Hiroaki Yanagimoto, Tetsuo Ajiki, Daisuke Tsugawa, Takuya Mizumoto, Shinichi So, Takeshi Urade, Yoshihide Nanno, Kenji Fukushima, Hidetoshi Gon, Syohei Komatsu, Kaori Kuramitsu, Tadahiro Goto, Sadaki Asari, Masahiro Kido, Hirochika Toyama, Takumi Fukumoto

  INTRODUCTION: Although the relationship between systemic inflammatory responses and prognosis has been known in various cancers, it remains unclear which scores are most valuable for determining the prognosis of extrahepatic cholangiocarcinoma. We aimed to verify the usefulness of various inflammation-based scores as prognostic factors in patients with resected extrahepatic cholangiocarcinoma. METHODS: We analyzed consecutive patients undergoing surgical resection for extrahepatic cholangiocarcinoma at our institution between January 2000 and December 2019. The usefulness of the following inflammation-based scores as prognostic factor was investigated: Glasgow prognostic score (GPS), modified Glasgow prognostic score (mGPS), neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), lymphocyte to monocyte ratio (LMR), prognostic nutrition index (PNI), C-reactive protein to albumin ratio (CAR), controlling nutritional status (CONUT), and prognostic index (PI). RESULTS: A total of 169 patients were enrolled in this study. Of the nine scores, CAR and CONUT indicated prognostic value. Furthermore, multivariate analysis for overall survival revealed that high CAR (>0.23) was an independent prognostic factor (HR: 1.816, 95%CI: 1.135-2.906, p=0.0129), along with lymph node metastasis and curability. There was no difference in tumor staging and short-term outcomes between the low CAR (≤ 0.23) and high CAR groups. CONCLUSIONS: CAR was the most valuable prognostic score in patients with resected extrahepatic cholangiocarcinoma.

  Jan. 2022, Digestive surgery, 39(2-3) (2-3), 65 - 74, English, International magazine

  Scientific journal


• Standardization of the Side-to-Side Cavo-Caval Anastomosis in Orthotopic Liver Transplantation Based on the Causal Analysis of Outflow Obstruction.

  Kaori Kuramitsu, Masahiro Kido, Shohei Komatsu, Daisuke Tsugawa, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Shinichi So, Takuya Mizumoto, Yoshihide Nanno, Hironori Yamashita, Tadahiro Goto, Hiroaki Yanagimoto, Sadaki Asari, Tetsuo Ajiki, Hirochika Toyama, Takumi Fukumoto

  BACKGROUND: Although liver transplantation is widely accepted as the therapeutic strategy for end-stage liver failure, complication of hepatic venous outflow obstruction remains lethal. Currently, ensuring a single wide orifice in both the graft and recipient inferior vena cava has been proposed to avoid hepatic venous outflow obstruction with no theoretical concept. METHODS: We herein report a standardization technique for the reconstruction of the hepatic vein based on the causal analysis. RESULTS: During the put-in process, the graft must be positioned in contact with the recipient diaphragm and slightly pushed to the cranial direction to simulate the state after abdominal closure. Because there is no extra space between the graft and diaphragm, the graft could not rotate about the anastomotic site of the inferior vena cava toward the diaphragm after abdominal closure as the intestinal pressure increases, and accordingly hepatic venous outflow obstruction does not develop. CONCLUSIONS: With this concept, all transplant surgeons can successfully and easily perform hepatic vein reconstruction without total clamping of the inferior vena cava and without outflow block.

  Dec. 2021, Transplantation proceedings, 53(10) (10), 2934 - 2938, English, International magazine

  Scientific journal


• Impact of Sarcopenia as a Prognostic Factor on Reductive Hepatectomy for Advanced Hepatocellular Carcinoma.

  Satoshi Omiya, Shohei Komatsu, Masahiro Kido, Kaori Kuramitsu, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Shinichi So, Keitaro Sofue, Yoshihiko Yano, Yoshitada Sakai, Hiroaki Yanagimoto, Hirochika Toyama, Tetsuo Ajiki, Takumi Fukumoto

  BACKGROUND/AIM: Sarcopenia has been reported to be a significant prognostic factor in patients with hepatocellular carcinoma in recent years. This study aimed to clarify the prognostic significance of sarcopenia in advanced hepatocellular carcinoma treated with reductive hepatectomy. PATIENTS AND METHODS: We retrospectively analyzed 93 patients who underwent reductive hepatectomy for advanced hepatocellular carcinoma. RESULTS: Median survival time of the sarcopenia group (16.4 months) was significantly shorter than that of the non-sarcopenia group (20.4 months). The overall survival rates at 1, 3, and 5 years of the sarcopenia group were significantly lower than those of the non-sarcopenia group (57.9%, 8.6%, and 2.9% vs. 67.3%, 29.2%, and 15.7%, respectively; p=0.035). On multivariate analysis, sarcopenia was a significant risk factor of overall survival (hazard ratio=1.60, 95% confidence interval=1.00-2.56, p=0.049). CONCLUSION: Sarcopenia was a significant prognostic factor of survival after reductive hepatectomy in advanced hepatocellular carcinoma.

  Nov. 2021, Anticancer research, 41(11) (11), 5775 - 5783, English, International magazine

  Scientific journal


• Lenvatinib Rechallenge After Ramucirumab Treatment Failure for Hepatocellular Carcinoma.

  Shohei Komatsu, Yoshihiko Yano, Masahiro Kido, Kaori Kuramitsu, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Shinichi So, Hiroaki Yanagimoto, Hirochika Toyama, Yuzo Kodama, Takumi Fukumoto

  BACKGROUND/AIM: While there is increasing evidence supporting the role of several first- and second-line treatment regimens for advanced hepatocellular carcinomas (HCC), the clinical relevance of rechallenge treatment with previously administered drugs, however, remains to be explored. PATIENTS AND METHODS: Five consecutive patients with advanced HCC who received lenvatinib rechallenge treatment after ramucirumab were assessed. RESULTS: All patients were clinically diagnosed with failure after ramucirumab treatment, and the frequencies of ramucirumab administration before lenvatinib re-administration ranged from 3 to 11. The alfa-fetoprotein level in four of five patients decreased 1 month after the lenvatinib rechallenge. Radiological findings via the modified Response Evaluation Criteria in Solid Tumors showed stable diseases in four patients and a partial response in one. CONCLUSION: Rechallenge treatment with lenvatinib after ramucirumab can be effective, and may be a treatment option for HCC in cases wherein the disease progressed after an initial response to lenvatinib treatment.

  Sep. 2021, Anticancer research, 41(9) (9), 4555 - 4562, English, International magazine

  Scientific journal


• A case of peripancreatic plexiform schwannoma.

  Kenji Fukushima, Makoto Shinzeki, Kentaro Tai, Masaki Omori, Natsuko Yamauchi, Tomoko Tanaka, Yasunori Matsuda, Hiroshi Ashitani, Kenichi Tanaka

  BACKGROUND: Plexiform schwannoma is one of the least common variants of schwannoma, accounting for only 5% of all schwannoma cases. It generally occurs in the skin and subcutaneous tissues and is uncommon in deep soft tissue or viscera. We present an extremely rare case of plexiform schwannoma arising from the peripancreatic plexus. CASE PRESENTATION: A 29-year-old man presented with hyperglycemia detected during a medical checkup. He was diagnosed with type 1 diabetes based on the clinical findings and laboratory tests. During the diagnostic process for diabetes, a 2.5 cm mass was incidentally detected in the pancreas by abdominal ultrasound. Contrast-enhanced computed tomography revealed a mass that was gradually enhanced at the body and tail of the pancreas. Magnetic resonance imaging revealed low signal intensity of the mass on T1-weighted images and high signal intensity on T2-weighted and diffusion-weighted images. Magnetic resonance cholangiopancreatography showed no abnormal findings in the main pancreatic duct. Endoscopic ultrasonography (EUS) showed a lobulated, low-echoic mass with a clear boundary. EUS-guided fine needle biopsy was performed, and spindle-shaped cells that were diffusely immunopositive for S-100 and negative for c-kit and desmin were detected, resulting in a diagnosis of a neurogenic tumor arising from the pancreas or the peripancreatic nerve plexus. The patient underwent laparoscopic spleen-preserving distal pancreatectomy. Although the tumor was connected to the splenic plexus, the splenic artery could be divided along its adventitial plane. Macroscopic findings of the excised tumor consisted of multiple yellowish-white nodules, and its histopathological features were consistent with plexiform schwannoma. There was no pancreatic tissue on the dorsal surface of the tumor, which suggested that the tumor arose from the peripancreatic nerve plexus. CONCLUSIONS: The findings documented herein can aid in the differential diagnosis of peripancreatic schwannoma and in planning appropriate treatment.

  Aug. 2021, Surgical case reports, 7(1) (1), 199 - 199, English, International magazine

  Scientific journal


• Severity assessment in pigs after partial liver resection: evaluation of a score sheet.

  Kerstin Hagemeister, Lisa Ernst, Pramod Kadaba Srinivasan, Hirokazu Tanaka, Kenji Fukushima, René Tolba

  Severity assessment in biomedical research is required by the European authorities. Therefore, a variety of score sheets are available. The first score sheets were designed and introduced by Morton and Griffith (M&G) in 1985, to assess pain and distress in animals. Score sheets are an important part of the 3R principles to evaluate the degree of severity in different studies. Here, we used a modified score sheet from M&G for severity assessment of 12 Aachen minipigs after partial liver resection for safety testing of a novel synthetic sealant (VIVO-107). The control group was treated with the clinical standard fibrin. Estimation of recovery status of both groups was performed from the day of surgery to postoperative day 7 using a score sheet. Included parameters were blood loss during the surgical procedure, general state, spontaneous behaviour and clinical results. Values from 0 to 20 were graded for each category and resulted in the degree of strain (DS) from DS0 to DS4. An increasing DS indicated higher severity. Suitability of the implemented score sheet was evaluated. Higher score points were documented almost exclusively as an outcome of the clinical results, influenced mainly by increased temperature in the fibrin treated control group, whereas, spontaneous behaviour had only slight influence and general state had no influence. The average score seven days after surgery was <2. The laparotomy, where the partial liver resection is a part, is rated as moderate severity in the EU Directive 2010/63, while the assessment done in the present study hints to a mild severity of the model in our hands.

  Jun. 2020, Laboratory animals, 54(3) (3), 251 - 260, English, International magazine

  Scientific journal


• Hemostatic Efficacy and Safety of the Novel Medical Adhesive, MAR VIVO-107, in a Rabbit Liver Resection Model.

  Kenji Fukushima, Hirokazu Tanaka, Pramod Kadaba Srinivasan, Kerstin Pawlowsky, Babette Kögel, Shinji Uemoto, Yonson Ku, René H Tolba

  BACKGROUND: Topical hemostatic agents are useful when hepatic hemorrhage is difficult to control. The aim of this study was to evaluate the hemostatic efficacy and safety of a biodegradable polyurethane-based adhesive, MAR VIVO-107 (MAR), in comparison with a clinically used fibrin glue. METHODS: Thirty female New Zealand white rabbits were randomly assigned to 3 study groups as follows: MAR (n = 10), fibrin glue (n = 10), and saline groups (n = 10). After standardized partial liver resection was performed, each agent was immediately applied to the wound area. Bleeding time until hemostasis and blood loss were recorded. After 7 days, body weight, hematology parameters, and serum levels of aspartate aminotransferase, alanine aminotransferase, and lactate dehydrogenase were measured. Simultaneously, the severity of intra-abdominal adhesion was evaluated. RESULTS: The mean bleeding time in the MAR (38 ± 10 s) and fibrin glue groups (65 ± 17 s) was significantly shorter than that in the saline group (186 ± 12 s). Similarly, the mean blood loss in the MAR (9 ± 3 g) and fibrin glue groups (9 ± 3 g) was significantly less than that in the saline group (23 ± 4 g). No significant differences in bleeding time and blood loss were found between the MAR and fibrin glue groups. The postoperative survival rate was 100% in all the groups. Body weight as well as hematological and serum biochemical values on day 7 were within the small and physiological range when compared with the preoperative baseline values, and significant differences were not detected among the MAR, fibrin glue, and saline groups. The severities of adhesion were similar between the 3 groups. CONCLUSION: Our data demonstrated that MAR was not inferior to fibrin glue in terms of hemostatic efficacy and safety.

  2018, European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes, 59(1-2) (1-2), 48 - 57, English, International magazine

  Scientific journal


• Efficacy of the Novel Medical Adhesive, MAR-VIVO-107, in an Acute Porcine Liver Resection Model.

  Hirokazu Tanaka, Kenji Fukushima, Pramod Kadaba Srinivasan, Kerstin Pawlowsky, Babette Koegel, Koichiro Hata, Yonson Ku, Shinji Uemoto, René H Tolba

  BACKGROUND: Despite modern surgical techniques, insufficient hemostasis after liver trauma is still a major cause of morbidity and mortality after injury. Therefore, efficient hemostatic agents are indicated. In this study, we evaluated the hemostatic efficacy of a novel synthetic wound adhesive (MAR-VIVO-107) based on polyurethane/polyurea, compared with a widely used fibrin adhesive (Tisseel). MATERIALS AND METHODS: Twelve German Landrace pigs were randomly assigned to 2 groups. The animals were operated under sterile conditions. A midline laparotomy was performed and the left liver lobe was isolated and resected, using a surgical scissor, in order to induce hepatic trauma. MAR-VIVO-107 or Tisseel was applied to the resected area. The animals were monitored for 60 minutes; thereafter, they were sacrificed under anesthesia. Blood and tissue samples were collected pre- and postresection for biochemical and hematological analyses. RESULTS: MAR-VIVO-107 versus Tisseel (mean ± SD, P value)-postsurgical survival rate was 100% in both groups. Bleeding time was significantly higher in Tisseel compared with MAR-VIVO-107 (10.3 ± 5.0 vs 3.7 ± 1.5 minutes, P = .0124). In trend, blood loss was less in the MAR-VIVO-107 group (54.3 ± 34.9 vs 105.5 ± 65.8 g, P = .222). Aspartate transaminase levels were significantly lower in the MAR-VIVO-107 group when compared with the Tisseel group (39.0 ± 10.0 vs 72.4 ± 23.4 U/L, P = .0459). CONCLUSION: The efficacy of MAR-VIVO-107 and comparable performance to the gold standard fibrin have been shown under pre-clinical conditions. MAR-VIVO-107 permits hemorrhage control within seconds, even in wet environment.

  Oct. 2017, Surgical innovation, 24(5) (5), 423 - 431, English, International magazine

  Scientific journal


• Novel synthetic adhesive as an effective alternative to Fibrin based adhesives.

  Pramod Kadaba Srinivasan, Vera Sperber, Mamdouh Afify, Hirokazu Tanaka, Kenji Fukushima, Babette Kögel, Felix Gremse, René Tolba

  AIM: To compare a novel, fully synthetic, polyurethane based glue (MAR-1) to fibrin sealant in a partial liver resection rat model. METHODS: After 50% resection of the lateral left liver lobe in male Wistar rats (n = 7/group/time point), MAR-1, Fibrin or NaCl was applied. After 14, 21 and 90 postoperative days, sealant degradation, intra-abdominal adhesions were scored, and histological examination of liver tissue was performed. RESULTS: (Mean ± SEM) (MAR-1 vs Fibrin vs NaCl). Bleeding mass was significantly higher in NaCl (3.36 ± 0.51 g) compared to MAR-1 (1.44 ± 0.40 g) and Fibrin (1.16 ± 0.32 g). At 14 and 90 d, bleeding time was significantly lower in MAR-1 (6.00 ± 0.9 s; 13.57 ± 3.22 s) and Fibrin (3.00 ± 0.44 s; 22.2 ± 9.75 s) compared to NaCl (158.16 ± 11.36 s; 127.5 ± 23.3 s). ALT levels were significantly higher in MAR-1 (27.66 ± 1 U/L) compared to Fibrin (24.16 ± 0.98 U/L) and NaCl (23.85 ± 0.80 U/L). Intrabdominal adhesions were significantly lower in MAR-1 (11.22% ± 5.5%) compared to NaCl (58.57% ± 11.83%). Degradation of the glue was observed and MAR-1 showed almost no traces of glue in the abdominal cavity as compared to the Fibrin (10% ± 5% 14 d; 7% ± 3% 21 d). Survival showed no significant differences between the groups. CONCLUSION: Compared to Fibrin, MAR-1 showed similar hemostatic properties, no adverse effects, and is biocompatible. Further studies on adhesion strength and biodegradability of synthetic sealants are warranted.

  Aug. 2017, World journal of hepatology, 9(24) (24), 1030 - 1039, English, International magazine

  Scientific journal


• Recommendation for severity assessment following liver resection and liver transplantation in rats: Part I.

  S Kanzler, A Rix, Z Czigany, H Tanaka, K Fukushima, B Kögel, K Pawlowsky, R H Tolba

  Score sheets were first introduced 30 years ago to assess pain, distress and suffering in animals. To date, however, there is still no general agreement on their use in research practice, and only a few publications can be found on this topic. In the present work, we demonstrate the use of a special score sheet for severity assessment in the first three postoperative days in two showcased studies performed on Wistar and Lewis rats undergoing liver resection or orthotopic liver transplantation, respectively. Scoring of different criteria and the total score were evaluated within each intervention. Additionally, both procedures were compared regarding their degree of severity. Suitability of these score sheets was evaluated for assessing severity of the procedures and these showed a minor severity within each investigated study. A comparison of both studies showed slightly higher scores involving liver transplantation. In contradiction to the common classification of these procedures as a moderate severity grade the score sheets applied here indicates a minor severity grade within each investigated study. Also, limitations and possible improvements in the design of our score sheets for defined interventions are reconsidered.

  Dec. 2016, Laboratory animals, 50(6) (6), 459 - 467, English, International magazine

  Scientific journal


• Severity assessment in rabbits after partial hepatectomy: Part II.

  N Drude, K Pawlowsky, H Tanaka, K Fukushima, B Kögel, R H Tolba

  Although the recognition of pain, distress and discomfort has already been described in 1985 by Morton and Griffiths there is still very little known about the establishment of score sheets especially, regarding post-surgical pain and severity assessment for laboratory animals such as rabbits. In this paper we describe the estimation of severity and recovery status of 36 female New Zealand White rabbits (NZW) in a standardized liver resection model using two different adhesive treatments and one control group. Welfare was assessed at 3-4 consecutive days after surgery using a scoring system which included the following criteria: body weight, general state, clinical results, spontaneous behavior and clinical examination. Values could range from 0 to 20 where increasing values indicated increasing severity with a predefined humane endpoint for a score ≥20 points. Documented score points were almost exclusively a result of body weight loss, whereas clinical signs and general health status had no influence on the overall sum of points scored. Behavioral variation was solely observed postoperatively, within the first 24 h, with an average score ≤1. In contrast to the classification of a laparotomy as a moderate procedure in the EU Directive 2010/63 (annex VIII) the assessment herein presented showed a mild burden in all groups according to the scoring system used. The partial hepatectomy itself, as well as the adhesive treatment using either synthetic glue VIVO-107 or fibrin glue, were well tolerated.

  Dec. 2016, Laboratory animals, 50(6) (6), 468 - 475, English, International magazine

  Scientific journal


• The Incidence of Posthepatectomy Liver Failure Defined by the International Study Group of Liver Surgery among Living Donors.

  Kaori Kuramitsu, Takumi Fukumoto, Tsuyoshi Kobayashi, Kenji Fukushima, Sho Okimoto, Takeshi Iwasaki, Masahiro Tominaga, Yoh Zen, Hideki Ohdan, Yonson Ku

  BACKGROUND: Although several publications have reported donor morbidities, deterioration of liver function, which may cause posthepatectomy liver failure (PHLF), was not assessed specifically. METHODS: The incidence of PHLF proposed by the International Study Group of Liver Surgery (ISGLS-PHLF) was analyzed among 257 living donors. ISGLS-PHLF was defined by an increased international normalized ratio and hyperbilirubinemia on or after postoperative day 5. RESULTS: ISGLS-PHLF was identified in 21 donors (8%), of which 18 (85.7%) were grade A, 2 (9.5%) were grade B, and 1 (4.8%) was grade C. The average hospital stay without ISGLS-PHLF was 15 ± 1 days, which extended along with increasing grades (p = 0.03). In univariate analysis, right hepatectomy was significantly associated with the incidence of ISGLS-PHLF (p = 0.02), and right hepatectomy (p = 0.002) and operation time (p = 0.01) in multivariate analysis. Of 176 right lobe donors, 19 (10.8%) developed ISGLS-PHLF, of which 16 (84.2%) were grade A, 2 (10.5%) were grade B, and 1 (5.3%) was grade C. Operation time was significantly associated with the incidence of ISGLS-PHLF in univariate (p = 0.002) and multivariate (p = 0.003) analyses. CONCLUSIONS: Right lobe donation surgery is associated with a higher incidence of ISGLS-PHLF.

  Apr. 2016, Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 20(4) (4), 757 - 64, English, International magazine

  Scientific journal


• Fabrication of a magnesium alloy with excellent ductility for biodegradable clips.

  Naoko Ikeo, Ryota Nakamura, Kosuke Naka, Toshiaki Hashimoto, Toshihiko Yoshida, Takeshi Urade, Kenji Fukushima, Hikaru Yabuuchi, Takumi Fukumoto, Yonson Ku, Toshiji Mukai

  UNLABELLED: To develop a biodegradable clip, the equivalent plastic strain distribution during occlusion was evaluated by the finite element analysis (FEA) using the material data of pure Mg. Since the FEA suggested that a maximum plastic strain of 0.40 is required to allow the Mg clips, the alloying of magnesium with essential elements and the control of microstructure by hot extrusion and annealing were conducted. Mechanical characterization revealed that the Mg-Zn-Ca alloy obtained by double extrusion followed by annealing at 673K for 2h possessed a fracture strain over 0.40. The biocompatibility of the alloy was confirmed here by investigating its degradation behavior and the response of extraperitoneal tissue around the Mg-Zn-Ca alloy. Small gas cavity due to degradation was observed following implantation of the developed Mg-Zn-Ca clip by in vivo micro-CT. Histological analysis, minimal observed inflammation, and an only small decrease in the volume of the implanted Mg-Zn-Ca clip confirmed its excellent biocompatibility. FEA using the material data for ductile Mg-Zn-Ca also showed that the clip could occlude the simulated vessel without fracture. In addition, the Mg-Zn-Ca alloy clip successfully occluded the renal vein. Microstructural observations using electron backscattering diffraction confirmed that dynamic recovery occurred during the later stage of plastic deformation of the ductile Mg-Zn-Ca alloy. These results suggest that the developed Mg-Zn-Ca alloy is a suitable material for biodegradable clips. STATEMENT OF SIGNIFICANCE: Since conventional magnesium alloys have not exhibited significant ductility for applying the occlusion of vessels, the alloying of magnesium with essential elements and the control of microstructure by hot extrusion and annealing were conducted. Mechanical characterization revealed that the Mg-Zn-Ca alloy obtained by double extrusion followed by annealing at 673K for 2h possessed a fracture strain over 0.40. The biocompatibility of the alloy was confirmed by investigating its degradation behavior and the response of extraperitoneal tissue around the Mg-Zn-Ca alloy. Finite element analysis using the material data for the ductile Mg-Zn-Ca alloy also showed that the clip could occlude the simulated vessel without fracture. In addition, the Mg-Zn-Ca alloy clip successfully occluded the renal vein. Microstructural observations using electron backscattering diffraction confirmed that dynamic recovery occurred during the later stage of plastic deformation of the ductile Mg-Zn-Ca alloy.

  Jan. 2016, Acta biomaterialia, 29, 468 - 476, English, International magazine

  Scientific journal


• INCIDENCE OF POSTHEPATECTOMY LIVER FAILURE AS DEFINED BY ISGLS AMONG LIVING LIVER DONORS

  Kaori Kuramitsu, Takumi Fukumoto, Masahiro Kido, Atsushi Takebe, Motofumi Tanaka, Hisoka Kinoshita, Kenji Fukushima, Taku Matsumoto, Tadahiro Gotoh, Sadaki Asari, Hirochika Toyama, Yonson Ku

  Nov. 2015, TRANSPLANT INTERNATIONAL, 28, 138 - 138, English


• [Successful Multimodal Treatment for Aggressive Extrahepatic Metastatic Hepatocellular Carcinoma - A Case Report].

  Hidetoshi Gon, Masahiro Kido, Takumi Fukumoto, Atsushi Takebe, Motofumi Tanaka, Kaori Kuramitsu, Hisoka Kinoshita, Kenji Fukushima, Takeshi Urade, Shinichi So, Makoto Shinzeki, Ippei Matsumoto, Tetsuo Ajiki, Yonson Ku

  A 38-year-old man underwent right hepatectomy for a huge hepatocellular carcinoma(HCC)in the right hepatic lobe. Four months later, recurrent and metastatic disease were observed in the remnant liver and right lung, respectively. We performed a hepatectomy for the recurrent lesion because transcatheter arterial chemoembolization (TACE) was not effective. After surgery, we initiated sorafenib treatment for the lung metastases. One year later, the lung metastases worsened and metastases were observed in the mediastinal lymph nodes, and both metastatic lesions were resected. Seven months later, para-aortic lymph nodal metastasis was observed and dissected. Three months later, metastasis to the supraclavicular lymph node was observed. We performed particle radiation therapy and a complete response was achieved. One year later, metastases in both lungs were observed and resected. Despite continued sorafenib administration throughout the clinical course, a metastasis to the left adrenal gland was observed. This lesion was extirpated because no other recurrent lesions were detected. At 4 years and 6 months after the first operation, no other recurrences have occurred. Currently, sorafenib is the initial drug of choice for HCC with extrahepatic metastases. It is possible to improve the prognosis of patients with HCC and extrahepatic metastases by applying surgical treatment during the course of sorafenib administration.

  Sep. 2015, Gan to kagaku ryoho. Cancer & chemotherapy, 42(9) (9), 1111 - 4, Japanese, Domestic magazine

  Scientific journal


• 肝細胞癌肝外転移巣に対し集学的治療を行い長期生存した1例

  権 英寿, 木戸 正浩, 福本 巧, 武部 敦志, 田中 基文, 蔵満 薫, 木下 秘我, 福島 健司, 浦出 剛史, 宗 慎一, 新関 亮, 松本 逸平, 味木 徹夫, 具 英成

  (株)癌と化学療法社, Sep. 2015, 癌と化学療法, 42(9) (9), 1111 - 1114, Japanese


• Severe post-transplant lymphoproliferative disorder after living donor liver transplantation.

  Kaori Kuramitsu, Takumi Fukumoto, Kenji Fukushima, Takeshi Iwasaki, Masahiro Tominaga, Toshimitsu Matsui, Fumi Kawakami, Tomoo Itoh, Yonson Ku

  Post-transplant lymphoproliferative disorder (PTLD) is a well-known complication after transplantation. A living donor liver transplantation was performed on a 31-year-old man for fulminant hepatitis. He again developed liver dysfunction after 7 months. He was diagnosed as having acute cellular rejection and the steroid pulse therapy introduced resulted in little improvement. He gradually developed a high fever and right axillary lymphadenopathy appeared. Chest computed tomography (CT) was performed revealing small lung nodules and axillary lymphadenopathy. Because his serological status for Epstein-Barr virus was positive, PTLD was highly suspected and immunosuppression treatment was withdrawn with little improvement. One week later, he developed tachycardia. Chest CT was re-performed revealing an infiltration to the left cardiac chamber. For diagnosis, axillary lymph node biopsy was performed and during the procedure, he developed ventricular tachycardia (VT). Immunohistological staining revealed PTLD of T lymphocytes, and chemotherapy was introduced on the same day he developed VT. After two cycles of tetrahydropyranyl, adriamycin, cyclophosphamide, vincristine, prednisolone and etoposide treatment, he completely recovered. This is a first case report of severe PTLD with VT, and our case implies the feasibility of chemotherapy after the appearance of dissemination symptoms.

  Mar. 2015, Hepatology research : the official journal of the Japan Society of Hepatology, 45(3) (3), 356 - 62, English, International magazine

  Scientific journal


• [A case of resection of a metastatic liver tumor that recurred after particle beam therapy].

  Toshihiko Yoshida, Atsushi Takebe, Takumi Fukumoto, Masahiro Kido, Motofumi Tanaka, Kaori Kuramitsu, Hisoka Kinoshita, Daisuke Tsugawa, Kenji Fukushima, Takeshi Urade, Shinichi So, Tetsuo Ajiki, Ippei Matsumoto, Makoto Shinzeki, Taro Okazaki, Sadaki Asari, Tadahiro Goto, Taku Matsumoto, Yonson Ku

  Recently, the indications for particle beam therapy have been expanded to include metastatic liver tumors. However, its adverse effects on the treated liver are unclear, and the possibility of local recurrence after treatment should not be ignored. A 65-year-old man with advanced rectal carcinoma underwent low anterior resection. Resectable metastatic liver tumors were detected after adjuvant chemotherapy; however, he opted to undergo particle beam therapy. Nine months after treatment, a local recurrence was detected around the treated area, and central bisegmentectomy of the liver was performed as a salvage operation. The operation was technically complicated owing to severe adhesions and inflammatory changes in the liver parenchyma around the treated area. Pathological examination revealed advanced liver fibrosis at the treated area, in contrast with normal parenchyma in the untreated area. Although the procedure requires advanced surgical techniques, salvage surgery is a feasible option for recurrent liver tumors after particle beam therapy.

  Nov. 2014, Gan to kagaku ryoho. Cancer & chemotherapy, 41(12) (12), 2071 - 3, Japanese, Domestic magazine

  Scientific journal


• [Long-term survival in a patient receiving multidisciplinary therapy for hepatocellular carcinoma with left iliac bone metastasis].

  Shinichi So, Masahiro Kido, Takumi Fukumoto, Atsushi Takebe, Motofumi Tanaka, Hisoka Kinoshita, Kaori Kuramitsu, Daisuke Tsugawa, Kenji Fukushima, Takeshi Urade, Toshihiko Yoshida, Sadaki Asari, Taro Okazaki, Makoto Shinzeki, Ippei Matsumoto, Tetsuo Ajiki, Yonson Ku

  The patient was a 79-year-old man diagnosed with a single 9.3-cm hepatocellular carcinoma (HCC) in the medial segment of the liver, and left iliac bone metastasis. Initially, the patient was treated with a hepatic arterial infusion of low-dose FP (cisplatin/5-fluorouracil) at another hospital. Here, the patient received particle therapy for the left iliac bone metastasis at a total dose of 52.8 Gy in 4 fractions. Subsequently, he underwent medial segmentectomy of the liver to treat the primary HCC. Eleven months later, the first intrahepatic recurrence occurred, and the tumor was treated with percutaneous radiofrequency ablation (RFA). A second intrahepatic recurrence was detected 39 months later, which was also treated with percutaneous RFA. The patient remains well, with no evidence of tumor recurrence.

  Nov. 2014, Gan to kagaku ryoho. Cancer & chemotherapy, 41(12) (12), 2107 - 9, Japanese, Domestic magazine

  Scientific journal


• 粒子線治療後に局所再発した転移性肝癌の1切除例

  吉田 俊彦, 武部 敦志, 福本 巧, 木戸 正浩, 田中 基文, 蔵満 薫, 木下 秘我, 津川 大介, 福島 健司, 浦出 剛史, 宗 慎一, 味木 徹夫, 松本 逸平, 新関 亮, 岡崎 太郎, 浅利 貞毅, 後藤 直大, 松本 拓, 具 英成

  (株)癌と化学療法社, Nov. 2014, 癌と化学療法, 41(12) (12), 2071 - 2073, Japanese


• 同時性腸骨転移を伴う肝細胞癌に対し集学的治療を行い長期生存を得た1例

  宗 慎一, 木戸 正浩, 福本 巧, 武部 敦志, 田中 基文, 木下 秘我, 蔵満 薫, 津川 大介, 福島 健司, 浦出 剛史, 吉田 俊彦, 浅利 貞毅, 岡崎 太郎, 新関 亮, 松本 逸平, 味木 徹夫, 具 英成

  (株)癌と化学療法社, Nov. 2014, 癌と化学療法, 41(12) (12), 2107 - 2109, Japanese


• Assessment of ISGLS definition of posthepatectomy liver failure and its effect on outcome in patients with hepatocellular carcinoma.

  Kenji Fukushima, Takumi Fukumoto, Kaori Kuramitsu, Masahiro Kido, Atsushi Takebe, Motofumi Tanaka, Tomoo Itoh, Yonson Ku

  BACKGROUND: Posthepatectomy liver failure (PHLF) is a major complication after hepatectomy. As there was no standardized definition, the International Study Group of Liver Surgery (ISGLS) defined PHLF as increased international normalized ratio and hyperbilirubinemia on or after postoperative day 5 in 2010. We evaluated the impact of the ISGLS definition of PHLF on hepatocellular carcinoma (HCC) patients. METHODS: We retrospectively analyzed 210 consecutive HCC patients who underwent curative hepatectomy at our facility from 2005 to 2010. The median follow-up period after hepatectomy was 35.2 months. RESULTS: Thirty-nine (18.6%) patients fulfilled the ISGLS definition of PHLF. Overall survival (OS) rates at 1, 3, and 5 years in patients with/without PHLF were 69.1/93.5, 45.1/72.5, and 45.1/57.8%, respectively (P = 0.002). Recurrence-free survival (RFS) rates at 1, 3, and 5 years in patients with/without PHLF were 40.9/65.9, 15.7/38.3, and 15.7/20.3%, respectively (P = 0.003). Multivariate analysis revealed that PHLF was significantly associated with both OS (P = 0.047) and RFS (P = 0.019). Extent of resection (P < 0.001), intraoperative blood loss (P = 0.002), and fibrosis stage (P = 0.040) were identified as independent risk factors for developing PHLF. CONCLUSION: The ISGLS definition of PHLF was associated with OS and RFS in HCC patients, and long-term survival will be improved by reducing the incidence of PHLF.

  Apr. 2014, Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 18(4) (4), 729 - 36, English, International magazine

  Scientific journal


• 肝細胞癌vp1症例術後再発形式の検討

  小松 昇平, 福本 巧, 木戸 正浩, 武部 敦志, 田中 基文, 蔵満 薫, 木下 秘我, 福島 健司, 浦出 剛史, 宗 慎一, 松本 逸平, 味木 徹夫, 千堂 宏義, 杉本 武巳, 藤野 泰宏, 富永 正寛, 具 英成

  (株)医薬情報研究所, Mar. 2014, 新薬と臨牀, 63(3) (3), 479 - 479, Japanese


• [Analysis of the safety and efficacy of percutaneous isolated hepatic perfusion after particle therapy for advanced hepatocellular carcinoma].

  Motofumi Tanaka, Takumi Fukumoto, Masahiro Kido, Atsushi Takebe, Kaori Kuramitsu, Hisoka Kinoshita, Shohei Komatsu, Kenji Fukushima, Takeshi Urade, Shinichi So, Makoto Shinzeki, Ippei Matsumoto, Tetsuo Ajiki, Kazuki Terashima, Osamu Fujii, Yusuke Demizu, Nobukazu Fuwa, Yonson Ku

  Here, we report the efficacy of dual treatment with hepatic resection and percutaneous isolated hepatic perfusion (PIHP) for advanced hepatocellular carcinoma( HCC). Recently, we introduced treatment with combined particle therapy and PIHP for unresectable HCC in cases of insufficient liver function. The purpose of this study was to evaluate the safety and efficacy of PIHP for local control in the liver after particle therapy. From 2006 to 2013, 6 patients underwent particle therapy for the main lesion and subsequent PIHP for remnant liver lesions. Their mean age was 64 years, and the mean size of the main lesion was 6.2 cm (range, 2.0-10.8 cm). All patients had liver cirrhosis. After particle therapy, PIHP was performed by hepatic arterial infusion of 100 mg/m2 of doxorubicin and 30 mg/m2 of mitomycin C. With regard to side effects, neutropenia occurred in all patients but no serious hepatobiliary injury was observed. The response rate for PIHP was 50% (partial response: 3 and stable disease: 3). The mean overall survival time was 26.9 months after particle therapy. In conclusion, even after particle therapy, PIHP is a safe treatment and is associated with a good local control rate for remnant HCCs. Further accumulation of data is needed to evaluate the efficacy of this treatment strategy in terms of prognosis.

  Nov. 2013, Gan to kagaku ryoho. Cancer & chemotherapy, 40(12) (12), 1681 - 3, Japanese, Domestic magazine

  Scientific journal


• 進行肝細胞癌に対する粒子線治療後にPIHPを施行した症例の検討

  田中 基文, 福本 巧, 木戸 正浩, 武部 敦志, 蔵満 薫, 木下 秘我, 小松 昇平, 福島 健司, 浦出 剛史, 宗 慎一, 新関 亮, 松本 逸平, 味木 徹夫, 寺嶋 千貴, 藤井 收, 出水 祐介, 不破 信和, 具 英成

  (株)癌と化学療法社, Nov. 2013, 癌と化学療法, 40(12) (12), 1681 - 1683, Japanese


• Dual Treatment; A Novel Strategy for Highly-Advanced Hepatocellular carcinoma

  Shinichi So, Takumi Fukumoto, Masahiro Kido, Atsushi Takebe, Motofumi Tanaka, Kaori Kuramitsu, Hisoka Kinoshita, Shohei Komatsu, Kenji Fukushima, Takeshi Urade, Yonson Ku

  Oct. 2013, HEPATOLOGY, 58, 230A - 230A, English


• Usefulness of 99mTc-GSA scintigraphy on preoperative evaluation of liver function for hepatectomy

  Motofumi Tanaka, Takumi Fukumoto, Masahiro Kido, Atsushi Takebe, Kaori Kuramitsu, Hisoka Kinoshita, Shohei Komatsu, Kenji Fukushima, Takeshi Urade, Shinichi So, Yonson Ku

  Oct. 2013, HEPATOLOGY, 58, 781A - 781A, English


• Graft Type Significantly Associates with the Incidence of Posthepatectomy Liver Failure Defined by ISGLS in Living Donors after Hepatectomy

  Kaori Kuramitsu, Takumi Fukumoto, Kenji Fukushima, Ippei Matsumoto, Tetsuo Ajiki, Yonson Ku

  Oct. 2013, HEPATOLOGY, 58, 775A - 775A, English


• 術前経皮的肝灌流と肝切除で完全奏効した両葉多発肝細胞癌の1例

  武部 敦志, 福本 巧, 木戸 正浩, 土田 忍, 高橋 応典, 田中 基文, 蔵満 薫, 中馬 正志, 福島 健司, 浦出 剛史, 外山 博近, 新関 亮, 松本 逸平, 味木 徹夫, 具 英成

  (株)医薬情報研究所, Dec. 2012, 新薬と臨牀, 61(12) (12), 2677 - 2677, Japanese


• [A case of bilobar multiple hepatocellular carcinoma in which complete remission was achieved by preoperative percutaneous isolated hepatic perfusion and subsequent hepatectomy].

  Takeshi Urade, Motofumi Tanaka, Takumi Fukumoto, Masahiro Kido, Shinobu Tsuchida, Masanori Takahashi, Atsushi Takebe, Kaori Kuramitsu, Masahide Awazu, Masashi Chuma, Kenji Fukushima, Shinichi So, Kentaro Tai, Masato Fujimoto, Hirochika Toyama, Makoto Shinzeki, Ippei Matsumoto, Tetsuo Ajiki, Yonson Ku

  We report a case of bilobar multiple hepatocellular carcinoma (HCC) successfully treated by preoperative percutaneous isolated hepatic perfusion(PIHP) and subsequent hepatectomy. A 77-year-old man with elevated serum PIVKA-II level and hepatomas was referred to our hospital. Abdominal dynamic computed tomography and gadoxetate disodium-enhanced magnetic resonance imaging demonstrated advanced HCCs: 11 tumors with a maximum tumor size of 4.8 cm diameter in the right lobe, and 1 tumor of 3.6 cm diameter in the left lobe. Curative resection was impossible due to insufficient liver function and due to the locations of the tumors. Therefore, we performed preoperative PIHP in order to control the multiple HCCs in the right lobe. This resulted in normalization of serum PIVKA-II level and complete necrosis of all tumors in the right lobe, as observed on dynamic computed tomography after 4 weeks of PIHP. Then, at 7 weeks after PIHP, we performed extended left lobectomy for residual tumor in the left lobe. Finally, complete remission was thought to have been achieved. The patient is alive 6 months after PIHP, without recurrence.

  Nov. 2012, Gan to kagaku ryoho. Cancer & chemotherapy, 39(12) (12), 1825 - 7, Japanese, Domestic magazine

  Scientific journal


• 術前経皮的肝灌流化学療法と肝切除にて完全奏効した両葉多発肝細胞癌の1例

  浦出 剛史, 田中 基文, 福本 巧, 木戸 正浩, 土田 忍, 高橋 応典, 武部 敦志, 蔵満 薫, 粟津 正英, 中馬 正志, 福島 健司, 宗 慎一, 田井 謙太郎, 藤本 将人, 外山 博近, 新関 亮, 松本 逸平, 味木 徹夫, 具 英成

  (株)癌と化学療法社, Nov. 2012, 癌と化学療法, 39(12) (12), 1825 - 1827, Japanese


• Long-Term Outcomes and Prognostic Factors with Reductive Hepatectomy and Sequential Percutaneous Isolated Hepatic Perfusion for Multiple Bilobar Hepatocellular Carcinoma

  Takumi Fukumoto, Masahiro Kido, Masanori Takahashi, Atsushi Takebe, Motofumi Tanaka, Kaori Kuramitsu, Kenji Fukushima, Takeshi Urade, Ippei Matsumoto, Tetsuo Ajiki, Yonson Ku

  Oct. 2012, HEPATOLOGY, 56, 518A - 519A, English


• Fragility Index, a Novel Predictor to Assess Deterioration Speed of Renal Function after Living Donor Liver Transplantation

  Kaori Kuramitsu, Takumi Fukumoto, Kenji Fukushima, Ippei Matsumoto, Tetsuo Ajiki, Yonson Ku

  Oct. 2012, HEPATOLOGY, 56, 519A - 519A, English


• [A case report of intrahepatic cholangiocarcinoma diagnosed as lung cancer with liver metastasis treated with radiofrequency ablation].

  Kenji Fukushima, Masahiro Kido, Takumi Fukumoto, Yuichi Hori, Nobuya Kusunoki, Shinobu Tsuchida, Masanori Takahashi, Motofumi Tanaka, Kaori Kuramitsu, Daisuke Tsugawa, Hidetoshi Gon, Masashi Chuma, Takeshi Urade, Ippei Matsumoto, Tetsuo Ajiki, Yonson Ku, Maki Kanzawa, Tomoo Ito

  In December 2008, a 43-year-old male who had been pointed out a nodular shadow in the right upper field on a chest radiography was admitted to hospital. A 35 mm mass infiltrating to superior vena cava in the right upper lobe of the lung, and 32 mm mass in the liver at S7 were detected by CT. Pathological diagnosis of the liver tumor was adenocarcinoma. Under the diagnosis of lung carcinoma and liver metastasis, systemic chemotherapy was started from January 2009. Radiofrequency ablation (RFA) therapy was added for liver S7 mass in February, and radiation therapy was performed for lung mass in December. The lung lesion has markedly reduced, but the liver lesion recurred in October 2009, which continued to grow up to 80 mm until August 2010. He presented to our hospital with the diagnosis of liver metastasis of controlled primary lung cancer. In October, we performed right hepatectomy with diaphragma and right lung resection. The pathological diagnosis was intrahepatic cholangiocarcinoma. Multiple recurrences in remnant liver, lung and peritoneal metastasis were detected in January 2011. For intrahepatic cholangiocarcinoma, hepatectomy is the only established treatment, and RFA treatment remains controversial. Clinical diagnosis of multiple cancers should be decided with caution.

  Nov. 2011, Gan to kagaku ryoho. Cancer & chemotherapy, 38(12) (12), 2030 - 2, Japanese, Domestic magazine

  Scientific journal


• [A case report of multiple advanced hepatocellular carcinomas treated by combination therapy with hepatectomy and particle therapy].

  Takeshi Urade, Masahiro Kido, Takumi Fukumoto, Yuichi Hori, Nobuya Kusunoki, Shinobu Tsuchida, Masanori Takahashi, Motofumi Tanaka, Kaori Kuramitsu, Daisuke Tsugawa, Hidetoshi Gon, Masashi Chuma, Kenji Fukushima, Ippei Matsumoto, Tetsuo Ajiki, Kazuki Terashima, Yusuke Demizu, Masao Murakami, Yonson Ku

  We report a case of multiple advanced hepatocellular carcinomas (HCC) with bilobar distribution treated by combination therapy of hepatectomy and particle therapy (carbon ion therapy). A 73-year-old man who had been pointed out hepatic tumors on abdominal CT was referred to our hospital in February 2010. Advanced HCCs; 8 cm Vp3 and 6 cm in the left lobe, 4 cm in the posterior segment, and 1 .5 cm in the S8 area, were detected by abdominal dynamic CT and EOB-MRI etc. Curative resection was not applied due to insufficiency of liver function and unfavorable anatomical tumor locations. Accordingly we have developed a novel combination therapy of hepatectomy and particle therapy. First we performed left lobectomy in March 2010, followed by administration of particle therapy to the posterior segment for local control in May. Then, transcatheter arterial chemoembolization was administered 4 times for residual tumors. The patient survives for 15 months after the initial therapy with good local control.

  Nov. 2011, Gan to kagaku ryoho. Cancer & chemotherapy, 38(12) (12), 2065 - 7, Japanese, Domestic magazine

  Scientific journal


• 肺癌肝転移の診断でRFAを施行した肝内胆管癌の1例

  福島 健司, 木戸 正浩, 福本 巧, 堀 裕一, 楠 信也, 土田 忍, 高橋 応典, 田中 基文, 蔵満 薫, 津川 大介, 権 英寿, 中馬 正志, 浦出 剛史, 松本 逸平, 味木 徹夫, 具 英成, 神澤 真紀, 伊藤 智雄

  (株)癌と化学療法社, Nov. 2011, 癌と化学療法, 38(12) (12), 2030 - 2032, Japanese


• 肝切除および粒子線治療併用にて治療効果を認めた両葉多発肝細胞癌の1例

  浦出 剛史, 木戸 正浩, 福本 巧, 堀 裕一, 楠 信也, 土田 忍, 高橋 応典, 田中 基文, 蔵満 薫, 津川 大介, 権 英寿, 中馬 正志, 福島 健司, 松本 逸平, 味木 徹夫, 寺嶋 千貴, 出水 祐介, 村上 昌雄, 具 英成

  (株)癌と化学療法社, Nov. 2011, 癌と化学療法, 38(12) (12), 2065 - 2067, Japanese


• RENAL FUNCTION DETERIORATES AFTER LIVING DONOR LIVER TRANSPLANTATION; HOW TO PREDICT CHRONIC DYSFUNCTION?

  Kaori Kuramitsu, Takumi Fukumoto, Shinobu Tuchida, Masahiro Kido, Masanori Takahashi, Motofumi Tanaka, Daisuke Tsugawa, Kenji Fukushima, Masashi Chuma, Takeshi Urade, Yonson Ku

  Oct. 2011, HEPATOLOGY, 54, 681A - 681A, English


• PERCUTANEOUS ISOLATED HEPATIC PERFUSION (PIHP) FOR ADVANCED HEPATOCELLULAR CARCINOMA: TWO DECADES EXPERIENCE OF KOBE PROGRAM

  Takumi Fukumoto, Nobuya Kusunoki, Masahiro Kido, Shinobu Tuchida, Masanori Takahashi, Motofumi Tanaka, Daisuke Tsugawa, Masashi Chuma, Kenji Fukushima, Takeshi Urade, Yonson Ku

  Oct. 2011, HEPATOLOGY, 54, 1385A - 1386A, English

• -

  -

  第38回日本内視鏡外科学会総会, Dec. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  第38回日本内視鏡外科学会総会, Dec. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  第38回日本内視鏡外科学会総会, Dec. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  第38回日本内視鏡外科学会総会, Dec. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  第38回日本内視鏡外科学会総会, Dec. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  第38回日本内視鏡外科学会総会, Dec. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  第38回日本内視鏡外科学会総会, Dec. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  第38回日本内視鏡外科学会総会, Dec. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  第38回日本内視鏡外科学会総会, Dec. 2025, Japanese, Domestic conference

  Public symposium


• -

  -

  第46回日本肝臓学会西部会, Dec. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  第19回肝臓内視鏡外科研究会, Nov. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  第19回肝臓内視鏡外科研究会, Nov. 2025, Japanese, Domestic conference

  Public symposium


• -

  -

  第19回肝臓内視鏡外科研究会, Nov. 2025, Japanese, Domestic conference

  Public discourse


• -

  -

  第23回日本消化器外科学会大会（JDDW2025）, Oct. 2025, Japanese, Domestic conference

  Poster presentation


• -

  -

  第23回日本消化器外科学会大会（JDDW2025）, Oct. 2025, Japanese, Domestic conference

  Poster presentation


• -

  -

  第23回日本消化器外科学会大会（JDDW2025）, Oct. 2025, Japanese, Domestic conference

  Poster presentation


• -

  -

  第23回日本消化器外科学会大会（JDDW2025）, Oct. 2025, Japanese, Domestic conference

  Poster presentation


• -

  -

  第23回日本消化器外科学会大会（JDDW2025）, Oct. 2025, Japanese, Domestic conference

  Poster presentation


• -

  -

  第23回日本消化器外科学会大会（JDDW2025）, Oct. 2025, Japanese, Domestic conference

  Poster presentation


• -

  -

  第23回日本消化器外科学会大会（JDDW2025）, Oct. 2025, Japanese, Domestic conference

  Poster presentation


• -

  -

  第23回日本消化器外科学会大会（JDDW2025）, Oct. 2025, Japanese, Domestic conference

  Public symposium


• -

  -

  第19回膵癌術前治療研究会, Oct. 2025, Japanese, Domestic conference

  Poster presentation


• -

  -

  第19回膵癌術前治療研究会, Oct. 2025, Japanese, Domestic conference

  Poster presentation


• -

  -

  第19回膵癌術前治療研究会, Oct. 2025, Japanese, Domestic conference

  Public symposium


• -

  -

  第61回日本移植学会総会, Oct. 2025, Japanese, Domestic conference

  Poster presentation


• -

  -

  第61回日本移植学会総会, Oct. 2025, Japanese, Domestic conference

  Poster presentation


• -

  -

  第61回日本移植学会総会, Oct. 2025, Japanese, Domestic conference

  Poster presentation


• -

  -

  第61回日本移植学会総会, Oct. 2025, Japanese, Domestic conference

  Poster presentation


• -

  -

  日本消化器病学会近畿支部第123回例会, Sep. 2025, Japanese, Domestic conference

  Public symposium


• -

  -

  第52回日本膵切研究会, Aug. 2025, Japanese, Domestic conference

  Poster presentation


• -

  -

  第52回日本膵切研究会, Aug. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Oral presentation


• A Case of Successful Conversion Hepatectomy Following Durvalumab plus Tremelimumab Therapy under Nasogastric Feeding for Advanced Vp4 Hepatocellular Carcinoma

  Sano H, Fukushima K, Komatsu S, Kido M, Urade T, So S, Yoshida T, Tai K, Arai K, Iguchi K, Nanno Y, Asari S, Yanagimoto H, Kodama T, Fukumoto T

  The 15th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE2025), Jul. 2025, English, International conference

  Poster presentation


• Impact of tumor size on liver regeneration after hepatectomy

  Takimoto D, Komatsu S, Kido M, Gon H, Fukushima K, Urade T, Yoshida T, Tai K, Arai K, Fujinaka R, Nanno Y, Asari S, Yanagimoto H, Fukumoto T

  The 15th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE2025), Jul. 2025, English, International conference

  Poster presentation


• Prognostic and predictive value of lymphocyte-to-monocyte transition in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab

  Omori M, Komatsu S, Tada T, ishihara N, Matsuura T, Ueshima E, Kido M, Gon H, Fukushima K, Urade T, Yoshida T, Tai K, Arai K, Yanagimoto H, Fukumoto T

  The 15th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE2025), Jul. 2025, English, International conference

  Poster presentation


• Evaluation of Nutritional Risk Assessment Methods for Hepatectomy in Hepatocellular Carcinoma

  Oji K, Urade T, Kido M, Komatsu S, Fukushima K, Yoshida T, Tai K, Arai K, Fukumoto T

  The 15th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE2025), Jul. 2025, English, International conference

  Poster presentation


• Outcomes and Indications of Curative Conversion Therapy After Immunotherapy

  Tai K, Komatsu S, Tada T, Matsuura T, Ueshima E, Omori M, Ishihara N, Kido M, Gon H, Fukushima K, Urade T, Yoshida T, Arai K, Yanagimoto H, Fukumoto T

  The 15th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE2025), Jul. 2025, English, International conference

  Poster presentation


• Impact of Initial Hepatectomy With Hilar Manipulation on Short-Term Outcomes of Repeat Hepatectomy for Recurrent Liver Cancer

  Arai K, Gon H, Komatsu S, Fukushima K, Kido M, Urade T, So S, Yoshida T, Tai K, Akita M, Yanagimoto H, Mizumoto T, Ishida J, Nanno Y, Fukumoto T

  The 15th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE2025), Jul. 2025, English, International conference

  Poster presentation


• Treatment strategy for Colorectal liver metastases based on liver resection and the benefit of preoperative chemotherapy

  Yoshida T, Komatsu S, Kido M, Gon H, Fukushima K, Urade T, So S, Tai K, Arai K, Iguchi K, Mizumoto T, Yanagimoto H, Fukumoto T

  The 15th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE2025), Jul. 2025, English, International conference

  Poster presentation


• Laparoscopic right posterior sectionectomy using the anterior approach for huge hepatocellular carcinoma

  Urade T, Kido M, Komatsu S, Fukushima K, So S, Yoshida T, Tai K, Arai K, Iguchi K, Mizumoto T, Ishida J, Nanno Y, Asari S, Yanagimoto H, Fukumoto T

  The 15th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE2025), Jul. 2025, English, International conference

  Poster presentation


• Impact of Post-Hepatectomy Liver Failure on Long-Term Liver Function and Prognosis in Patients with Hepatocellular Carcinoma

  Fukushima K, Komatsu S, Kido M, Urade T, So S, Yoshida T, Tai K, Arai K, Iguchi K, Mizumoto T, Ishida J, Nanno Y, Asari S, Yanagimoto H, Fukumoto T

  The 15th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE2025), Jul. 2025, English, International conference

  Poster presentation


• Prognostic and predictive value of lymphocyte-to-monocyte transition in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab

  Omori M, Komatsu S, Tada T, ishihara N, Matsuura T, Ueshima E, Kido M, Gon H, Fukushima K, Urade T, Yoshida T, Tai K, Arai K, Yanagimoto H, Fukumoto T

  The 15th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE2025), Jul. 2025, English, International conference

  Oral presentation


• Commentators(Session 8a)

  Fukushima K

  The 15th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE2025), Jul. 2025, English, International conference

  Oral presentation


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jun. 2025, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jun. 2025, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Jun. 2025, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Jun. 2025, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Jun. 2025, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Jun. 2025, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Jun. 2025, Japanese, Domestic conference

  Poster presentation


• Comparison of short-term outcomes between open and laparoscopic surgery for multiple liver resections

  Takimoto D, Urade T, Kido M, Komatsu S, Gon H, Fukushima K, Yoshida T, Tai K, Arai K, Yanagimoto H, Toyama H, Fukumoto T

  -, Jun. 2025, English, International conference

  Poster presentation


• Impact of malnutrition on short- and long-term outcomes in laparoscopic liver resection for hepatocellular carcinoma

  Oji K, Urade T, Kido M, Komatsu S, Fukushima K, So S, Yoshida T, Tai K, Arai K, Fukumoto T

  -, Jun. 2025, English, International conference

  Oral presentation


• Re-staining method with indocyanine green fluorescence imaging for laparoscopic liver resection

  Urade T, Kido M, Komatsu S, Gon H, Fukushima K, Yoshida T, Tai K, Arai K, Yanagimoto H, Toyama H, Fukumoto T

  -, Jun. 2025, English, International conference

  Oral presentation


• Nutritional Status Assessed by GLIM and PNI as Predictors of Textbook Outcome in Liver Resection for Hepatocellular Carcinoma

  Oji K, Urade T, Kido M, Komatsu S, Gon H, Fukushima K, Yoshida T, Arai K, Yanagimoto H, Toyama H, Fukumoto T

  -, Jun. 2025, English, Domestic conference

  Poster presentation


• Acase of T1b ampullary adenocarcinoma with para-aortic lymph node metastasis

  Takahashi T, Yanagimoto H, Tsugawa D, Akita M, Urade T, Fukushima K, Gon H, Komatsu S, Toyama H, Kido M, Fukumoto T

  -, Jun. 2025, English, Domestic conference

  Poster presentation


• Effects of simultaneous portal and hepatic vein ligation for the induction of liver regeneration: Arat model of liver venous deprivation

  Fujinaka R, Urade T, Kido M, Komatsu S, Gon H, Fukushima K, Yoshida T, Asari S, Yanagimoto H, Toyama H, Fukumoto T

  -, Jun. 2025, English, Domestic conference

  Poster presentation


• Anomalous origin of the posterior superior pancreaticoduodenal artery (PSPDA): critical vascular variations in the field of hepato-pancreato-biliary surgery

  Okazoe Y, Yanagimoto H, Tsugawa D, Akita M, Fukushima K, Gon H, Komatsu S, Asari S, Toyama H, Kido M, Fukumoto T

  -, Jun. 2025, English, Domestic conference

  Poster presentation


• Association between S-1 postoperative adjuvant chemotherapy and early postoperative recurrence in biliary tract cancer

  Yoshida M, Yanagimoto H, Tsugawa D, Akita M, Fukushima K, Gon H, Komatsu S, Asari S, Kido M, Toyama H, Fukumoto T

  -, Jun. 2025, English, Domestic conference

  Poster presentation


• Utility of oncological resectability criteria for recurrent hepatocellular carcinoma after hepatectomy

  Ishihara N, Komatsu S, Omori M, Tai K, Kido M, Gon H, Fukushima K, Urade T, Yanagimoto H, Toyama H, Fukumoto T

  -, Jun. 2025, English, Domestic conference

  Poster presentation


• Outcomes of Immune Checkpoint Inhibitors for Recurrent Hepatocellular Carcinoma After Major Hepatectomy or sectionectomy

  Tai K, Komatsu S, Kido M, Gon H, Fukushima K, Urade T, Yoshida T, Arai K, Yanagimoto H, Toyama H, Fukumoto T

  -, Jun. 2025, English, Domestic conference

  Poster presentation


• Aretrospective study on the accuracy of preoperative diagnosis of pancreatic carcinoma in situ

  Mizumoto T, Toyama H, Nanno Y, Ishida J, Urade T, Fukushima K, Komatsu S, Yanagimoto H, Asari S, Fukumoto T

  -, Jun. 2025, English, Domestic conference

  Poster presentation


• Identifying the Best Nutritional Prognostic Marker for Survival in Pancreatic Ductal Adenocarcinoma Patients

  Nanno Y, Toyama H, Ishida J, Mizumoto T, Fukushima K, Gon H, Tsugawa D, Komatsu S, Yanagimoto H, Kido M, Fukumoto T

  -, Jun. 2025, English, Domestic conference

  Poster presentation


• Re-staining method with indocyanine green fluorescence imaging for laparoscopic anatomical liver resection

  Urade T, Kido M, Komatsu S, Gon H, Fukushima K, Yoshida T, Tai K, Arai K, Yanagimoto H, Toyama H, Fukumoto T

  -, Jun. 2025, English, Domestic conference

  Poster presentation


• Comparison of the utility of liver reserve and fibrosis indicators in predicting posthepatectomy liver failure after right hepatectomy for hepatocellular carcinoma

  Fukushima K, Komatsu S, Kido M, Gon H, Urade T, Yoshida T, Tai K, Arai K, Yanagimoto H, Toyama H, Fukumoto T

  -, Jun. 2025, English, Domestic conference

  Poster presentation


• Prognosis of hepatectomy versus systemic chemotherapy based on oncological resectability criteria for borderline resectable hepatocellular carcinoma

  Komatsu S, Tanaka M, Takebe A, Ishihara N, Kido M, Gon H, Fukushima K, Urade T, Nanno Y, Yanagimoto H, Fukumoto T

  -, Jun. 2025, English, Domestic conference

  Public symposium


• -

  -

  -, Jun. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, May 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, May 2025, Japanese, Domestic conference

  Public symposium


• -

  -

  -, May 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2025, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Mar. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Mar. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Mar. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Mar. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Feb. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jan. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jan. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jan. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jan. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Dec. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Dec. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Dec. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Dec. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Dec. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Dec. 2024, Japanese, Domestic conference

  Nominated symposium


• -

  -

  -, Dec. 2024, Japanese, Domestic conference

  Nominated symposium


• -

  -

  -, Dec. 2024, Japanese, Domestic conference

  Nominated symposium


• -

  -

  -, Dec. 2024, Japanese, Domestic conference

  Nominated symposium


• -

  -

  -, Nov. 2024, Japanese, Domestic conference

  Nominated symposium


• -

  -

  -, Nov. 2024, Japanese, Domestic conference

  Nominated symposium


• -

  -

  -, Nov. 2024, Japanese, Domestic conference

  Nominated symposium


• -

  -

  -, Oct. 2024, English, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2024, English, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2024, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2024, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2024, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2024, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2024, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2024, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2024, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2024, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2024, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Oct. 2024, English, International conference

  Public symposium


• -

  -

  -, Sep. 2024, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Sep. 2024, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Sep. 2024, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Sep. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Aug. 2024, English, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2024, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Jul. 2024, English, International conference

  Poster presentation


• -

  -

  -, Jul. 2024, English, International conference

  Poster presentation


• -

  -

  -, Jul. 2024, English, International conference

  Poster presentation


• -

  -

  -, Jul. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2024, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jul. 2024, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jun. 2024, English, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2024, English, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2024, English, Domestic conference

  Public symposium


• -

  -

  -, Jun. 2024, English, Domestic conference

  Public symposium


• -

  -

  -, Jun. 2024, English, Domestic conference

  Public symposium


• -

  -

  -, Jun. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2024, English, International conference

  Poster presentation


• -

  -

  -, Jun. 2024, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jun. 2024, Japanese, Domestic conference

  Invited oral presentation


• -

  -

  -, Jun. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, May 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2024, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2024, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2024, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2024, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2024, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2024, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2024, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2024, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2024, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2024, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2024, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2024, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2024, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2024, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Mar. 2024, Japanese, International conference

  Poster presentation


• -

  -

  -, Mar. 2024, Japanese, International conference

  Poster presentation


• -

  -

  -, Mar. 2024, Japanese, International conference

  Oral presentation


• -

  -

  -, Mar. 2024, Japanese, International conference

  Oral presentation


• -

  -

  -, Mar. 2024, Japanese, International conference

  Oral presentation


• -

  -

  -, Mar. 2024, Japanese, Domestic conference

  Others


• -

  -

  -, Feb. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Feb. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jan. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jan. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Dec. 2023, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Dec. 2023, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Nov. 2023, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Nov. 2023, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Nov. 2023, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Nov. 2023, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Nov. 2023, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Nov. 2023, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Nov. 2023, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Nov. 2023, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Nov. 2023, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Nov. 2023, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Nov. 2023, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Nov. 2023, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Nov. 2023, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Nov. 2023, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Nov. 2023, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Nov. 2023, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Nov. 2023, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Nov. 2023, English, International conference

  Poster presentation


• -

  -

  -, Oct. 2023, English, International conference

  Poster presentation


• -

  -

  -, Sep. 2023, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Sep. 2023, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Sep. 2023, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Sep. 2023, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Sep. 2023, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Sep. 2023, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Sep. 2023, Japanese, Domestic conference

  Poster presentation


• A comparative study of laparo-scopic liver resection for the segment 8 dorsal and ventral area

  -

  -, Sep. 2023, English, International conference

  Oral presentation


• Short-term impact of laparoscopic liver resection with 0-mm surgical margin for HCC

  -

  -, Sep. 2023, English, International conference

  Oral presentation


• Acceptability of Laparoscopic Liver Resection of Segment I: A Retrospective Study

  -

  -, Sep. 2023, English, International conference

  Oral presentation


• Laparoscopic segmentectomy2 versus left lateral sectionecto-my for liver tumors in segment2

  -

  -, Sep. 2023, English, International conference

  Oral presentation


• Impact of malnutrition diagnosed by the GLIM criteria on postoperative complications after pancreaticoduodenectomy for biliary tract cancer

  -

  -, Sep. 2023, English, International conference

  Poster presentation


• Impact of malnutrition diagnosed by the GLIM criteria on outcome of elderly patients with hepatocellular carcinoma after liver resection

  -

  -, Sep. 2023, English, International conference

  Poster presentation


• -

  -

  -, Sep. 2023, Japanese, Domestic conference

  Invited oral presentation


• -

  -

  -, Aug. 2023, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2023, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2023, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jul. 2023, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jul. 2023, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2023, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2023, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2023, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2023, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2023, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2023, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jun. 2023, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Jun. 2023, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Jun. 2023, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Jun. 2023, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Jun. 2023, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2023, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2023, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2023, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2023, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jun. 2023, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jun. 2023, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jun. 2023, English, International conference

  Oral presentation


• -

  -

  -, Jun. 2023, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2023, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2023, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2023, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2023, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2023, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2023, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jun. 2023, Japanese, Domestic conference

  Public symposium


• -

  -

  -, May 2023, English, International conference

  Poster presentation


• -

  -

  -, May 2023, English, International conference

  Poster presentation


• -

  -

  -, Apr. 2023, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2023, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2023, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2023, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2023, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2023, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2023, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2023, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2023, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2023, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2023, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2023, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2023, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2023, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2023, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2023, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2023, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2023, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Apr. 2023, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Apr. 2023, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Apr. 2023, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Apr. 2023, Japanese, Domestic conference

  Others


• -

  -

  -, Apr. 2023, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2023, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2023, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2023, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2023, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Mar. 2023, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jan. 2023, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Dec. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Dec. 2022, English, International conference

  Oral presentation


• -

  -

  -, Dec. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Dec. 2022, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Dec. 2022, Japanese, Domestic conference

  Public symposium


• The Factors of Predicting Over-Time Weight Increase After Liver Transplantation

  Shimura Y, Kuramitsu K, Kido M, Komatsu S, Gon H, Fukushima K, Urade T, So S, Tsugawa D, Goto T, Asari S, Yanagimoto H, Toyama H, Fukumoto T

  -, Nov. 2022, English, International conference

  Oral presentation


• -

  -

  -, Nov. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Nov. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Nov. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Nov. 2022, Japanese, Domestic conference

  Public symposium


• The usefulness of total tumor volume as a prognostic factor with colorectal cancer liver metastases

  Shimura Y, Komatsu S, Kido M, Kuramitsu K, Gon H, Fukushima K, Urade T, So S, Mizumoto T, Nanno Y, Tsugawa D, Goto T, Asari S, Yanagimoto H, Toyama H, Ajiki T, Fukumoto T

  -, Oct. 2022, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2022, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2022, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2022, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2022, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2022, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2022, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2022, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2022, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2022, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2022, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2022, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2022, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2022, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2022, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2022, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2022, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2022, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2022, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2022, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Oct. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Oct. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Oct. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Sep. 2022, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Sep. 2022, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Sep. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Sep. 2022, English, International conference

  Poster presentation


• -

  -

  -, Aug. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2022, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jul. 2022, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jul. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2022, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jul. 2022, English, International conference

  Oral presentation


• -

  -

  -, Jun. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2022, Japanese, Domestic conference

  Invited oral presentation


• -

  -

  -, Jun. 2022, Japanese, Domestic conference

  Public symposium


• Impact of Delayed Gastric Emptying After Pancreatoduodenectomy on Postoperative Nutritional Status

  Mizumoto T, Toyama H, Asari S, Goto T, Nanno Y, So S, Urade T, Fukushima K, Gon H, Tsugawa D, Komatsu S, Kuramitsu K, Yanagimoto H, Kido M, Ajiki T, Fukumoto T

  -, Jun. 2022, Japanese, Domestic conference

  Poster presentation


• Spontaneous rupture of splenic hilar lymph node metastasis from hepatocellular carcinoma: a rare case report

  Fujinaka R, Urade T, Kido M, Kuramitsu K, Komatsu S, Gon H, Fukushima K, So S, Mizumoto T, Nanno Y, Tsugawa D, Goto T, Asari S, Yanagimoto H, Toyama H, Ajiki T, Fukumoto T

  -, Jun. 2022, Japanese, Domestic conference

  Poster presentation


• Laparoscopic anatomic liver resection of segment 2 based on the anatomical variation of the hepatic veins

  Urade T, Kido M, Kuramitsu K, Komatsu S, Gon H, Fukushima K, Mizumoto T, Nanno Y, Tsugawa D, Goto T, Yanagimto H, Asari S, Toyama H, Ajiki T, Fukumoto T

  -, Jun. 2022, Japanese, Domestic conference

  Poster presentation


• Low levels of C-reactive protein on postoperative day 1 are an early predictor for posthepatectomy liver failure in hepatocellular carcinoma patients undergoing right hepatectomy

  Fukushima K, Kido M, Kuramitsu K, Komatsu S, Gon H, Urade T, So S, Mizumoto T, Nanno Y, Tsugawa D, Goto T, Asari S, Yanagimoto H, Toyama H, Ajiki T, Fukumoto T

  -, Jun. 2022, Japanese, Domestic conference

  Poster presentation


• Current role of atezolizumab plus bevacizumab therapy in the sequential treatment of unresectable hepatocellular carcinoma

  Komatsu S, Kido M, Kuramitsu K, Gon H, Fukushima K, Urade T, So S, Mizumoto T, Nanno Y, Tsugawa D, Goto T, Asari S, Yanagimoto H, Toyama H, Ajiki T, Fukumoto T

  -, Jun. 2022, Japanese, Domestic conference

  Poster presentation


• Utility of plasma serum D-dimer for diagnosis of venous thromboembolism after hepatectomy

  Yanagimoto H, Miyake T, Tsugawa D, Urade T, Nanno Y, Fukushima K, Gon H, Komatsu S, Kuramitsu K, Goto T, Asari S, Kido M, Toyama H, Ajiki T, Fukumoto T

  -, Jun. 2022, Japanese, Domestic conference

  Poster presentation


• The usefulness of total tumor volume as a prognostic factor in patients with colorectal cancer liver metastases

  Shimura Y, Komatsu S, Kido M, Kuramitsu K, Gon H, Fukushima K, Urade T, So S, Mizumoto T, Nanno Y, Tsugawa D, Goto T, Asari S, Yanagimoto H, Toyama H, Ajiki T, Fukumoto T

  -, Jun. 2022, Japanese, Domestic conference

  Public symposium


• Multidisciplinary approach for advanced hepatocellular carcinoma

  Kido M, Komatsu S, Kuramitsu K, Gon H, Fukushima K, Urade T, Ajiki T, Yanagimoto H, Goto T, Tsugawa D, Toyama H, Fukumoto T

  -, Jun. 2022, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jun. 2022, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Jun. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, May 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, May 2022, Japanese, Domestic conference

  Public symposium


• -

  -

  -, May 2022, Japanese, Domestic conference

  Public symposium


• -

  -

  -, May 2022, Japanese, Domestic conference

  Public symposium


• -

  -

  -, May 2022, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Apr. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2022, Japanese, Domestic conference

  Oral presentation


• Intraoperative Assessment of the Demarcation Line and Intersegmental/Sectional Planes in Liver Surgery

  Urade T, Kido M, Kuramitsu K, Komatsu S, Gon H, Fukushima K, So S, Mizumoto T, Nanno Y, Tsugawa D, Goto T, Asari S, Yanagimoto H, Toyama H, Ajiki T, Fukumoto T

  15th World Congress of the International Hepato-Pancreato-Biliary Association (IHPBA), Mar. 2022, English, International conference

  Poster presentation


• Laparoscopic anatomic liver resection of segment 2 by glissonean approach

  Urade T, Kido M, Kuramitsu K, Komatsu S, Gon H, Fukushima K, So S, Mizumoto T, Nanno Y, Goto T, Asari S, Yanagimoto H, Toyama H, Ajiki T, Fukumoto T

  SAGES 2022 Annual Meeting, Mar. 2022, English, International conference

  Poster presentation


• -

  -

  -, Feb. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Dec. 2021, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Dec. 2021, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Dec. 2021, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Dec. 2021, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Dec. 2021, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Dec. 2021, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Dec. 2021, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Dec. 2021, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Nov. 2021, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Nov. 2021, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Oct. 2021, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Oct. 2021, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Sep. 2021, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Sep. 2021, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Oct. 2015, Japanese, Domestic conference

  Poster presentation


• Incidence of posthepatectomy liver failure as defined by ISGLS among living liver donors

  Kuramitsu K, Fukumoto T, Kido M, Takebe A, Tanaka M, Kinoshita H, Fukushima K, Matsumoto T, Goto T, Asari S, Toyama H, Ku Y

  17th Congress of the European Society for Organ Transplantation (ESOT Brussels 2015), Sep. 2015, English, International conference

  Oral presentation


• A case of outflow block requiring metallic stent of inferior vena cava and hepatic vein after orthotopic liver transplantation using piggyback technique

  Arai K, Tanaka M, Fukumoto T, Kuramitsu K, Kido M, Takebe A, Kinoshita H, Fukushima K, Urade T, So S, Yoshida T, Ku Y

  14th Congress of the Asian Society of Transplantation (CAST2015), Aug. 2015, English, International conference

  Poster presentation


• -

  -

  -, Jul. 2015, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jun. 2015, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Jun. 2015, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Jun. 2015, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jun. 2015, Japanese, Domestic conference

  Public symposium


• -

  -

  -, May 2015, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2015, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Apr. 2015, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Nov. 2014, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Nov. 2014, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Nov. 2014, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Nov. 2014, Japanese, Domestic conference

  Public symposium


• Low-dose antiviral treatment for hepatitis C virus following living donor liver transplantation without splenectomy

  Yoshida T, Takebe A, Fukumoto T, Kido M, Tanaka M, Kuramitsu K, Kinoshita H, Fukushima K, Urade T, Ku Y

  The 1st International Congress of Living Donor Liver Transplantation Study Group(ILDLT), Nov. 2014, English, International conference

  Poster presentation


• -

  -

  -, Oct. 2014, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Jul. 2014, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jul. 2014, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2014, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2014, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2014, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2014, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2014, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2014, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jun. 2014, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jun. 2014, Japanese, Domestic conference

  Public symposium


• -

  -

  -, May 2014, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, May 2014, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Apr. 2014, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2014, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2014, Japanese, Domestic conference

  Poster presentation


• A novel algorithm for hepatectomy based on the fibrosis stage

  Kuramitsu K, Fukumoto T, Fukushima K, Kido M, Takebe A, Tanaka M, Kinoshita H, Matsumoto I, Ajiki T, Ku Y

  11th World Congress of the International Hepato-Pancreato-Biliary Association(IHPBA), Mar. 2014, English, International conference

  Poster presentation


• Dual treatment; A novel strategy for highly-Advanced hepatocellular carcinoma

  So S, Kido M, Fukumoto T, Takebe A, Tanaka M, Kinoshita H, Kuramitsu K, Tsugawa D, Fukushima K, Ku Y

  11th World Congress of the International Hepato-Pancreato-Biliary Association(IHPBA), Mar. 2014, English, International conference

  Poster presentation


• -

  -

  -, Nov. 2013, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Nov. 2013, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Nov. 2013, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Nov. 2013, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Nov. 2013, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Nov. 2013, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Nov. 2013, English, Domestic conference

  Oral presentation


• -

  -

  -, Nov. 2013, English, International conference

  Poster presentation


• -

  -

  -, Nov. 2013, English, International conference

  Poster presentation


• -

  -

  -, Nov. 2013, English, International conference

  Poster presentation


• -

  -

  -, Nov. 2013, English, International conference

  Poster presentation


• -

  -

  -, Oct. 2013, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2013, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2013, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2013, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Sep. 2013, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Sep. 2013, Japanese, International conference

  Oral presentation


• -

  -

  -, Jul. 2013, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2013, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jul. 2013, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2013, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2013, Japanese, Domestic conference

  Nominated symposium


• -

  -

  -, Jul. 2013, English, International conference

  Poster presentation


• -

  -

  -, Jul. 2013, English, International conference

  Poster presentation


• -

  -

  -, Jul. 2013, English, International conference

  Poster presentation


• -

  -

  -, Jul. 2013, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2013, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2013, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jun. 2013, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jun. 2013, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jun. 2013, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jun. 2013, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Jun. 2013, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Jun. 2013, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2013, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jun. 2013, Japanese, Domestic conference

  Public symposium


• -

  -

  -, May 2013, Japanese, Domestic conference

  Public symposium


• -

  -

  -, May 2013, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Apr. 2013, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2013, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2013, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2013, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2013, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2013, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2013, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2013, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jan. 2013, English, International conference

  Poster presentation


• -

  -

  -, Dec. 2012, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Nov. 2012, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Nov. 2012, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Nov. 2012, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Nov. 2012, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Nov. 2012, English, International conference

  Poster presentation


• -

  -

  -, Nov. 2012, English, International conference

  Poster presentation


• -

  -

  -, Oct. 2012, English, International conference

  Poster presentation


• -

  -

  -, Oct. 2012, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Sep. 2012, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2012, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2012, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2012, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2012, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2012, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2012, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2012, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jun. 2012, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jun. 2012, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jun. 2012, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jun. 2012, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Jun. 2012, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Jun. 2012, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jun. 2012, Japanese, Domestic conference

  Public symposium


• -

  -

  -, May 2012, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, May 2012, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, May 2012, Japanese, Domestic conference

  Public symposium


• -

  -

  -, May 2012, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, May 2012, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2012, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2012, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Mar. 2012, English, Domestic conference

  Oral presentation


• -

  -

  -, Mar. 2012, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Feb. 2012, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Dec. 2011, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Nov. 2011, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Nov. 2011, English, International conference

  Poster presentation


• -

  -

  -, Nov. 2011, English, International conference

  Poster presentation


• -

  -

  -, Oct. 2011, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2011, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Sep. 2011, English, International conference

  Poster presentation


• -

  -

  -, Sep. 2011, Japanese, Domestic conference

  Public discourse


• -

  -

  -, Sep. 2011, English, International conference

  Poster presentation


• -

  -

  -, Sep. 2011, English, International conference

  Poster presentation


• -

  -

  -, Jul. 2011, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Jul. 2011, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Jul. 2011, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Jul. 2011, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2011, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2011, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2011, English, International conference

  Poster presentation


• -

  -

  -, Jul. 2011, English, International conference

  Poster presentation


• -

  -

  -, Jun. 2011, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jun. 2011, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jun. 2011, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Feb. 2011, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Nov. 2010, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Nov. 2007, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Sep. 2007, Japanese, Domestic conference

  Oral presentation